Introduction {#s1}
============

G-quadruplex-DNA (G4-DNA) is a higher-order nucleic acid structure formed by guanine (G)-rich sequences. Co-planar associations of four guanines into G-quartets self-stack to form highly thermodynamically stable G4-DNA complexes, which are further stabilized by potassium cations. These structures are important in DNA replication, telomere maintenance, and regulation of transcription, at least in cancer cells ([@bib74]; [@bib58]). Putative G4-DNA forming sequences (PQFSes) are ubiquitous in the human genome: more than 300,000 PQFSes have been identified *in silico* and more than 700,000 G4-DNA sequences by G4-seq ([@bib15]). These sequences are frequent in oncogenes and regulatory and homeostatic genes ([@bib20]; [@bib39]). Intriguingly, the number of the G4-DNA structures varies between cancerous cell lines, indicating that 'active' G4-DNA structures and G4-DNA landscapes might be cell-type dependent ([@bib36]).

The importance of G4-DNA in cellular homeostasis has been further supported by the discovery of G4-DNA binding proteins. Various proteins, including G4-DNA unwinding helicases ([@bib75]) (*e.g.,* Pif1 [@bib69]) and several transcription factors ([@bib55]; [@bib30]; [@bib48]), bind to the G4-DNA structures and, therefore, may regulate transcription of specific genes. G4-DNA downregulates gene expression by preventing transcription factor binding to the gene promoter or stalling RNA polymerase. Stabilized G4-DNA must be unfolded for transcription to occur. In contrast, the G4-DNA structures may enhance the expression of certain genes by facilitating transcription factor binding to these genes or their promoters ([@bib10]; [@bib47]; [@bib77]) or by keeping the gene 'open' and, thus, enabling re-initiation of transcription ([@bib10]; [@bib77]; [@bib19]; [@bib18]).

Recently, we demonstrated that PQFSes are located in the promoter region of the *Brca1* gene and in the *Brca1* gene itself and that pharmacologically stabilizing G4-DNA downregulates *Brca1* gene and promotes DNA damage in neurons ([@bib64]). However, whether G4-DNA regulates gene expression of other genes in highly transcriptionally active neurons is not known. Additionally, G4-DNA was recently implicated in neurodegenerative disorders, such as frontotemporal dementia and amyotrophic lateral sclerosis ([@bib34]). In aged cells, intriguingly, guanines within DNA are often oxidized, and oxidation stabilizes G-quadruplexes ([@bib33]), therefore making these non-canonical structures an attractive research target in neurodegeneration and brain aging research.

Macroautophagy (referred to as autophagy hereafter) is a fundamental cellular process by which cells sequester and degrade proteins, damaged or unwanted organelles, and parasites ([@bib29]). Thus, autophagy is critical for cell survival and maintenance, development, inflammation and immune responses, DNA repair, proteostasis, organelle quality control, and prevention of cellular senescence and aging ([@bib29]). Mice with enhanced basal autophagy exhibit increased healthspan and lifespan ([@bib24]), but those with defective autophagy develop neurodegenerative disease--like symptoms, indicating that autophagy plays a vital role in neural maintenance and survival ([@bib44]). To sequester cytoplasmic content, autophagy involves the use of autophagosomes, double-membrane vesicles, which subsequently fuse to lysosomes for degradation ([@bib29]). Autophagy is orchestrated by the autophagy-related (ATG) evolutionarily conserved genes that nucleate the autophagosomal precursor phagophore and elongate the autophagosome, engulf cytoplasmic cargo, and fuse the autophagosome with the lysosome ([@bib29]). Autophagy is regulated by transcription and translation, as well as by protein post-translational modifications and autophagic proteins' half-lives ([@bib38]; [@bib57]). A decrease in autophagic activity with aging leads to the accumulation of damaged and senescent cellular components in all cell types of aging organisms ([@bib17]). The expression of many critical autophagic genes, such as *Atg5* and *Atg7,* decreases with aging ([@bib53]; [@bib56]), which can also be epigenetically regulated, at least in part ([@bib52]; [@bib28]). Intriguingly, G4 ligands *stimulate* autophagy in cancer cells ([@bib7]; [@bib68]; [@bib87]). Whether G4-DNA structures can regulate autophagy in neurons or are altered with aging is not known.

ATG7, an E1-like enzyme, critical for the initiation of autophagy, couples LC3-I to the E2-like enzyme ATG3 leading to the E3-like complex of ATG16L1/ATG5-ATG12 to conjugate LC3-I to phosphatidylethanolamine in phagophore membranes ([@bib29]). Mice deficient in genes involved in the ATG conjugation system, including *Atg7,* die within 1 day after birth because autophagy is strongly upregulated immediately after birth as an adaptation mechanism ([@bib46]). Models of neurodegeneration, such as alpha-synucleinopathy and brain samples from patients with Lewy Body disease, show that ATG7 is downregulated, reflecting reduced and defective autophagy, and endogenously raising ATG7 by a lentiviral delivery decreases the levels of alpha-synuclein and mitigates neurodegeneration ([@bib16]). *Atg7*-deficient neurons in the midbrain of conditional *Atg7* knock-out mice degenerate and are accompanied by the formation of ubiquitinated inclusion bodies ([@bib27]). Importantly, the expression of *Atg7* goes down in the human brain during normal aging ([@bib53]). It is not clear what mechanisms regulate *Atg7* expression.

In this study, we investigated whether G4-DNA regulates neuronal autophagy. We discovered that stabilizing G4-DNA with two distinct G4-DNA-binding ligands, pyridostatin (PDS) and BRACO19, downregulates the ATG7 protein, lowers *Atg7* mRNA, and inhibits autophagy in cultured primary neurons. We also found that, in an in vitro gel-shift assay, an antibody specific to the G4-DNA binds to a synthetic oligonucleotide, which corresponds to a G4-forming sequence in the first intron of the *Atg7* gene. The G4-DNA-binding protein PC4 also binds to this oligonucleotide from the *Atg7* gene. We discovered that mice treated with PDS exhibit memory deficits and accumulate lipofuscin, a hallmark of aged brains. Brain samples from aged mice contained G4-DNA structures that are not present in brain samples from young mice. In cultured primary neurons exposed to PDS, overexpressing the G4-DNA helicase Pif1, a G4-DNA helicase that unwinds the G-quadruplex structures even in the presence of G4-DNA-binding drugs ([@bib88]), improves autophagic phenotypes induced by PDS treatment. Our findings suggest that the G4-DNA structures might be an important pathway during brain aging and neurodegeneration.

Results {#s2}
=======

Autophagic genes contain PQFSes {#s2-1}
-------------------------------

We hypothesized that many autophagy genes can be regulated by G4-DNA. First, we investigated whether the ATG genes contain putative G4-DNA motifs. We used the QGRS mapper (<http://bioinformatics.ramapo.edu/QGRS/index.php>) to identify the PQFSes in these genes (mouse, rat and human). Analyses revealed that all these genes contain PQFSes, suggesting that G4-DNA may be involved in the regulation of their expression ([Figure 1](#fig1){ref-type="fig"}).

![PQFS in the gene and the promoter sequence of autophagy genes.\
The number of PQFS in the listed genes and their promoter were analyzed by using the QGRS mapper (<http://bioinformatics.ramapo.edu/QGRS/index.php>). \* 5000 nucleotides upstream the gene were considered as the promoter sequence; \*\* Data not available.\
Figure 1---source data 1.PQFS in the gene and the promoter sequence of autophagy genes.](elife-52283-fig1){#fig1}

PDS and BRACO19 downregulate *Atg7* in neurons {#s2-2}
----------------------------------------------

ATG7 is important for autophagosome biogenesis ([@bib29]). The rat *Atg7* gene contains 27 putative sequences that can arrange into G4-DNA. There are no PQFSes in the *Atg7* gene promoter (upstream, 5 kb) ([Figure 2a](#fig2){ref-type="fig"}). We first determined if PDS alters *Atg7*'s mRNA levels in primary cultured neurons ([Figure 2b](#fig2){ref-type="fig"}). After PDS treatment, mRNA was extracted and analyzed by qRT-PCR. We found that the levels of *Atg7*'s mRNA were sevenfold lower in neurons exposed to the G4 ligand than in neurons treated with a vehicle. *Tbp* (TATA-binding protein) mRNA was used as loading control as neither *Tbp* nor its promoter contains a PQFS ([@bib64]). We next tested if the levels of the ATG7 protein are changed in neuronal cells treated with PDS. Cultured neurons were treated with PDS, and cellular extracts were analyzed by western blotting. The levels of the ATG7 protein in PDS-treated neurons were half those of control neurons ([Figure 2c,d](#fig2){ref-type="fig"}). We confirmed these findings with another well-established G4 ligand, BRACO-19 ([@bib35]). Similarly, BRACO-19 reduced the levels of *Atg7* mRNA and ATG7 by twofold in neurons ([Figure 2e,f,g](#fig2){ref-type="fig"}).

![PDS downregulates ATG7 levels in primary neurons.\
(**a**) A scheme of the rat *Atg7* gene and its promoter showing putative G4-DNA locations. (**b--d**) Cultured primary neurons were treated with a vehicle (control, cont) or with PDS (2 μM) overnight. Neurons were collected and processed to measure mRNA (**b**) and levels of ATG7 (**c,d**). (**b**) Expression levels of *Atg7* and *Tbp* (housekeeping protein as control) were determined by qRT-PCR. \*\*\*p(*Atg7*)=0.0001 (t-test). n.s., non-significant, p(*Tbp*)=0.426. Results were pooled from three independent experiments. (**c**) The protein levels of ATG7 were determined by western blotting. Actin was used as a loading control. (**d**) Quantification of ATG7 protein levels normalized to actin from (**c**). \*\*\*p=0.0001 (t-test). Results were pooled from four independent experiments. (**e--g**) Cultured primary neurons were treated with a vehicle (control, cont) or with BRACO19 (2 μM) overnight. Neurons were collected and processed to measure mRNA (**e**) and levels of ATG7 (**f,g**). (**e**) The expression of *Atg7* and *Tbp* was determined by qRT-PCR. \*\*\*p(*Atg7*)=0.0001 (t-test). n.s., non-significant, p(*Tbp*)=0.662. Results were pooled from three independent experiments. (**f**) Levels of ATG7 were determined by western blotting. Actin was used as a loading control. (**g**) Quantification of ATG7 protein was normalized to actin from (**f**). \*\*\*p=0.0001 (t-test). Results were pooled from four independent experiments.](elife-52283-fig2){#fig2}

A PQFS in the *Atg7* gene folds into a G4 motif in vitro and in vivo {#s2-3}
--------------------------------------------------------------------

G4-DNA sequences have been extensively studied in vitro. We examined whether the sequence discovered in the *Atg7* gene folds into a G4 structure in vitro. We first identified a 32-nt sequence with the highest QGRS score (G-score = 67; see Materials and methods) in the *Atg7* gene ([Figure 3a](#fig3){ref-type="fig"}). Whether this sequence, named Atg7-32 (d\[^5'^G**~3~**GCTGG**~3~**TC~3~T~2~GG**~3~**A~2~CTGTAT~2~G**~3~**^3'^\]), is able to fold into a G4 structure ([Figure 3b](#fig3){ref-type="fig"}) was investigated by circular dichroism (CD) and thermal difference spectra (TDS) ([@bib60]). CD and TDS signatures clearly indicated that Atg7-32 indeed folds into a mixture of different topological quadruplex structures ([Figure 3c,d](#fig3){ref-type="fig"}). These signatures were expected in view of the nature of the intervening sequences between the guanine-runs (from 2-nt to 9-nt loops), which might also form duplex stems. The variety of the Atg7-32 G4-DNA structures can be reduced by dehydrating conditions with PEG200 and CH~3~CN ([@bib12]), leading to the typical CD (negative at 242 nm and positive at 264 nm) and TDS (positive at 273 nm and negative at 296 nm) signatures of a G4-DNA structure ([Figure 3c,d](#fig3){ref-type="fig"}). Similar experiments were performed with a modified Atg7-32 sequence (named mutAtg7-32) that cannot fold into a G4-DNA structures because of seven G-to-C replacements (underlined) within the four G-runs of the Atg7-32 sequence (d\[^5′^G[C]{.ul}G[C]{.ul}CTG[C]{.ul}G[C]{.ul}TC~3~T~2~G[C]{.ul}G[C]{.ul}A~2~CTGTAT~2~G[C]{.ul}G^3′^\]). We found that mutAtg7-32 display signatures typical of a GC-rich duplex (CD signals at 255 (negative) and 285 nm (positive); TDS signals at 240 and 276 nm), thus confirming the G4 topological unicity of Atg7-32 ([Figure 3c,d](#fig3){ref-type="fig"}). We further investigated the higher-order structure of both Atg7-32 and mutAtg7-32 by nuclear magnetic resonance (NMR). Both displayed ^1^H-NMR signals in the 12--14 ppm region, which corresponds to duplex stems (providing a rationale for the complicated CD/TDS signature of the former), but only Atg7-32 had ^1^H-NMR signals in the 10--12 ppm region, characteristic of a G4-DNA structure (poorly defined here, demonstrating a mixture of G4 topologies) ([Figure 3e](#fig3){ref-type="fig"}). These signals indicate that Atg7-32 may fold into a variety of G4-DNA topologies, including both 3- and 4-G-quartet G4s with both short (2-nt) and long (9-nt) hairpin-forming loops ([Figure 3b](#fig3){ref-type="fig"}), which were also detected earlier in non-neuronal cells ([@bib15]; [@bib72]) or computationally predicted ([@bib8]; [@bib73]). An equilibrium among all these various topologies is illustrated by the complex signatures generated with CD, TDS and NMR.

![A PQFS in the *Atg7* gene folds into a G4 structure in vitro.\
(**a**) Scheme of the rat *Atg7* gene and its promoter showing the sequence of the Atg7-32 and ATG2700 oligonucleotides that corresponds to a putative G4-forming sequence. (**b**) Scheme of the G-rich sequence under its unfolded (left) and folded structures (G4-DNA, right); guanines are shown as gray squares, with detailed chemical structures of guanine (left) and G-quartets (right). Atg7-32 may fold into multiple conformations that include both 3- and 4-G-quartet G4s with both short (2-nt) and long (9-nt) hairpin-forming loops. An equilibrium between all these various topologies is illustrated by the complex signatures generated with CD, TDS and NMR (see **c--e**). (**c**) Circular dichroism (CD) generated from 3 μM Atg7-32 (plain lines) and mutAtg7-32 (dotted lines) in 10 mM lithium cacodylate buffer plus 10 mM KCl and 90 mM LiCl (Caco.K10) in absence (black lines) or presence dehydrating agent (PEG200, 20% v/v, brown line, or acetonitrile, 50% v/v, red plain line and gray dotted line for Atg7-32 and mutAtg7-32, respectively). (**d**) Thermal difference spectra (TDS) generated from 3 μM Atg7-32 (plain lines) and mutAtg7-32 (dotted lines) in Caco.K10 in absence (black lines) or presence of acetonitrile (50% v/v, red plain line and gray dotted line for Atg7-32 and mutAtg7-32, respectively). (**e**) Nuclear magnetic resonance (NMR) of 200 μM Atg7-32 (upper panel) and mutAtg7-32 (lower panel) in Caco.K10. (**f**) Chemical structures of PDS and BRACO19. (**g--h**) FRET-melting curves (**g**) and results (**h**) for experiments performed with 0.2 μM fam-Atg7-32-tamra (**g,h**) and fam-mutAtg7-32-tamra (**h**) in absence (black line) or presence of increasing concentrations of PDS (0.2--1.0 μM, blue lines), (**g,h**) and BRACO19 (**h**) in CacoK.10.](elife-52283-fig3){#fig3}

We next investigated whether and how PDS and BRACO-19 ([Figure 3f](#fig3){ref-type="fig"}) interact with Atg7-32 and mutAtg7-32 in vitro. We found that both ligands strongly stabilize the Atg7-32 G4 structure against thermal denaturation (*via* a FRET-melting assay, using doubly labeled Atg7-32 and mutAtg7-32 sequences, see Methods), delaying melting by 22°C and 14°C for PDS and BRACO-19, respectively, while interacting only moderately with the mutAtg7-32 hairpin structure, delaying its melting by 3°C and 4°C only for PDS and BRACO-19, respectively ([Figure 3g,h](#fig3){ref-type="fig"}). Overall, these data confirm that Atg7-32 folds into a G4-DNA structure in vitro that can be stabilized by G4-ligands.

A longer version of the Atg7-32 motif, with 6-nt extensions on both its 5′- and 3′-ends, named ATG2700 (d\[^5′^AT~2~CT~2~G**~3~**GCTGG**~3~**TC~3~T~2~GG**~3~**A~2~CTGTAT~2~G**~3~**TGA~2~C~2~^3′^\]), was used to assess whether it can be recognized by the G4-specific antibody HF2 ([Figure 4a](#fig4){ref-type="fig"}). We synthesized both Cy5-labeled ATG2700 and SS-DNA, a control that cannot fold into a G4 structure. The HF2 antibody was incubated with ATG2700 and SS-DNA in buffers with either K^+^, which favors G4, or Li^+^, which prevents G4 formation ([Figure 4a,b](#fig4){ref-type="fig"}). We found that HF2 interacts with ATG2700 only in K^+^-rich conditions ([Figure 4a](#fig4){ref-type="fig"}), without binding to the control SS-DNA. Our data thus indicate that the PQFS identified in the *Atg7* gene indeed adopts a G4 structure in vitro. These findings were further confirmed with a well-established G4-binding protein, PC4. Yeast PC4 (Sub1) and human PC4 (hPC4) were overexpressed in yeast and lysates were incubated with ATG2700 and SS-DNA, immobilized on beads. Yeast and human PC4 only interact with ATG2700 ([Figure 4c,d](#fig4){ref-type="fig"}), further demonstrating the G4 nature of the *Atg7*'s G4.

![The HF2 antibody and PC4 bind to the ATG2700 oligonucleotide in vitro, and the N-TASQ probe detects G4-DNA in vivo.\
(**a--b**) Cy5-conjugated ATG2700 and SS-DNA (a negative control) oligonucleotides were heat-denatured and then slow-cooled in the presence of K^+^ (KCl) or Li^+^ (LiCl) to allow the formation of a secondary structure. 1.5 pmoles of each oligonucleotides (oligo) and 0 (a buffer alone), 10 or 20 ng of the HF2 antibody were incubated in a buffer, which contained 100 mM KCl (**a**) or 100 mM LiCl (**b**). Note in (**a**) that the bands at the top of the gel correspond to the ATG2700 oligonucleotide bound to the HF2 antibody in samples incubated with a buffer containing KCl. However, note in (**b**) that the gel lacks of bands at the top. (**c--d**) Yeast were transformed with a DNA construct that express yeast Sub1-FLAG (**c**) or with a DNA construct that express human PC4-HIS (**d**). Yeast were collected and lysed, and extracts were incubated with ATG2700 or SS-DNA (negative control) oligonucleotides. Immunoprecipitates were immobilized with agarose beads, and protein complexes were then run in a gel and analyzed by western blotting with antibodies against FLAG (**c**) or antibodies against HIS (**d**). (**e**) Cultured primary neurons were treated with a vehicle (control, cont) or with PDS (2 μM) overnight. Cells were fixed and stained with N-TASQ (50 μM), with antibodies against MAP2c, and with the nuclear dye Hoechst (DAPI). White arrows depict N-TASQ-positive puncta. Scale bar, 10 µm (**f**) N-TASQ fluorescence intensities were analyzed from (**e**). \*\*\*p(cont vs PDS)=0.0001 (t-test). For each experiment, 200 neurons were analyzed, and results were pooled from three independent experiments.](elife-52283-fig4){#fig4}

Finally, to confirm that the G4s can be detected in vivo, cultured primary neurons were treated with a vehicle or PDS or BRACO19 and then stained with N-TASQ, a G4-DNA-selective fluorophore that has been used to gauge the changes in a G4 landscape in cancer cells treated with G4 ligands ([@bib49]; [@bib50]; [@bib84]). We discovered that PDS- and BRCAO19-treated neurons exhibit higher levels of N-TASQ fluorescence than control cells ([Figure 4e,f](#fig4){ref-type="fig"}, and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These data indicate that G4 ligands modulate a G4 landscape in cultured primary neurons, suggesting a mechanism of how G4 stabilization downregulates *Atg7*.

PDS inhibits neuronal autophagy {#s2-4}
-------------------------------

To confirm that autophagy is downregulated by PDS, we measured autophagic flux in live neurons. We used an optical pulse-chase labeling method based on the photoswitchable protein Dendra2 and longitudinal imaging ([@bib80]; [@bib6]; [@bib81]). Brief irradiation with short wavelength visible light ('photoswitch') irreversibly changes the conformation of 'green' Dendra2 and its fluorescence to the 'red' form ([Figure 5a](#fig5){ref-type="fig"}). The Dendra2-based optical pulse-chase labeling has been applied to study autophagic flux ([@bib6]; [@bib62]), protein degradation (*e.g.,* wild-type and mutant huntingtin) ([@bib81]), the dynamics and turnover of synaptic proteins ([@bib83]), and mitochondrial dynamics ([@bib70]). Cultured cortical neurons were transfected with Dendra2-LC3 (LC3 is a marker of autophagy [@bib43]; [@bib61]), photoswitched, treated with PDS or vehicle, and followed with an automated microscope for several days. The red fluorescence intensities from individual cells were measured at different time points. Decay of the red fluorescence were plotted against time, transformed into log values; the half-lives from individual neurons were analyzed and normalized. Expectedly, the half-life of Dendra2-LC3 (*e.g.,* the decay of photoswitched 'red' Dendra2 signal) was prolonged by PDS by 1.7-fold, indicating slowed flux through autophagy ([Figure 5b](#fig5){ref-type="fig"}). Beclin1 ([@bib86]), a constitutive protein within the pre-autophagosomal complex used as a positive control, reduced the Dendra2-LC3 half-life by twofold, indicating that the flux through autophagy was increased, as expected ([Figure 5b](#fig5){ref-type="fig"}).

![PDS inhibits autophagy in cultured primary neurons.\
(**a**) The photoswitchable protein Dendra2 is commonly used to measure the half-life of a protein of interest. A brief irradiation with short-wavelength visible light induces an irreversible conformational change ('photoswitch', indicated by a blue arrow) in Dendra2. Photoswitched Dendra2 emits red fluorescence that can be tracked overtime with an automated microscope. Scale bar, 10 µm. (**b**) Dendra2 was fused to LC3, an autophagy marker, to measure autophagy flux. Two cohorts of primary neurons were co-transfected with Dendra2-LC3 and an empty plasmid, or with Dendra2-LC3 and untagged beclin1 (Becn1, as a positive control). Neurons co-transfected with Dendra2-LC3 and an empty plasmid were treated with a vehicle (control, cont), or with 0.1 µM PDS overnight. After treatment, neurons were longitudinally imaged, and the decay of the red fluorescence over time was used to calculate the half-life of Dendra2-LC3. The half-life of Dendra2-LC3 is normalized to one with respect to control neurons. \*p(cont vs Becn1)=0.02, \*\*p(cont vs PDS)=0.001, \*\*p(Becn1 vs PDS)=0.001 (one-way ANOVA). One hundred neurons per group were analyzed from two independent experiments. (**c**) Cultured primary neurons were treated with a vehicle or with PDS (2 µM), in combination with the autophagy enhancer 10-NCP (NCP, 1 µM) overnight. Neurons were collected, and pellets were lysed and analyzed by western blotting with antibodies against LC3-II and against actin. (**d**) Quantification of LC3-II levels normalized to actin from (**c**). \*\*p(cont vs NCP+PDS)=0.008, \*\*\*p(cont vs NCP)=0.0001, \*\*\*p(NCP vs NCP+PDS)=0.0002 (one-way ANOVA). Results were pooled from four independent experiments. (**e**) Dendra2 was fused to Htt^ex1^-Q~46~, an autophagy substrate, to measure autophagy flux. Two cohorts of primary neurons were transfected with Dendra2- Htt^ex1^-Q~46~. 24 hr after transfection, neurons were treated with a vehicle (control, cont), or with PDS (0.1 µM), and longitudinally imaged. The decay of the red fluorescence over time was used to calculate the half-life of Dendra2- Htt^ex1^-Q~46~. The half-life of Dendra2- Htt^ex1^-Q~46~ is normalized to one with respect to control neurons. \*\*p(cont vs PDS)=0.0064 (t-test). Fifty neurons per group were analyzed from two independent experiments. (**f**) Fluorescence images of a neuron co-transfected with the DNA constructs TagBFP and mito-Keima. Keima is a fluorescent pH-sensitive protein used as a reporter of subcellular acidic environments. Keima emits green fluorescence in neutral environments, and emits red light in acidic environments, such as lysosomes or autolysosomes. Targeting Keima to mitochondria has been used to study a specific form of autophagy, mitophagy. Note that a white arrow depicts mitochondria in acidic compartment (red channel). (**g**) Two cohorts of primary neurons were transfected with mito-Keima. 24 hr after transfection, neurons were treated with a vehicle (control, cont) or with 0.1 µM PDS, and imaged 48 hr after treatment. Quantification of red fluorescence intensity of mito-Keima indicates that mitophagy is reduced in PDS-treated neurons. \*\*\*p(cont vs PDS)=0.0001, (t-test). One hundred neurons per group were analyzed from three independent experiments.](elife-52283-fig5){#fig5}

We previously discovered a series of small molecules that induce autophagy in primary neurons ([@bib79]). Among them, the benzoxazine derivative 10-NCP promotes neuronal autophagy and protects neurons from misfolded proteins ([@bib62]; [@bib79]; [@bib65]). This compound enhances the formation of autophagosomes and stimulates the lipidation of LC3-I to LC3-II, reflecting enhanced autophagy ([@bib79]; [@bib65]). We, therefore, wondered if G4 ligands could reduce and/or prevent 10-NCP-induced lipidation of LC3-I. Primary cortical neurons were treated with PDS, with or without 10-NCP ([Figure 5c,d](#fig5){ref-type="fig"}). We discovered that PDS completely prevented 10-NCP-mediated formation of LC3-II. In addition, we used BRACO19 alone or in combination with 10-NCP to confirm if lipidation of LC3-II is also inhibited in neurons by an alternative G4 ligand ([Figure 5---figure supplement 1a,b](#fig5s1){ref-type="fig"}). BRACO19 reduced the LC3-II levels by 0.8-fold, leading to the conclusion that the initial stages of autophagy are inhibited by G4 ligand treatment, which likely arise from downregulated levels of ATG7, at least in part.

10-NCP, as an autophagy enhancer, regulates the degradation of mutant huntingtin (mHtt) ([@bib79]) in neurons, the protein that causes Huntington's disease. To confirm that PDS modulates autophagic substrates, we transfected neurons with the exon-1 fragment of polyQ-expanded mHtt (mHtt^ex1^) tagged with Dendra2 and treated them with PDS or vehicle. Importantly, we confirmed that neither the plasmid promoter (pGW1 [@bib2]) nor the mHtt^ex1^ contain putative G4s with QGRS mapper analyses. We found that the half-life of mHtt^ex1^-Dendra2 was increased in neurons exposed to PDS by 1.4-fold ([Figure 5e](#fig5){ref-type="fig"}). We then used the BACHD mouse model to confirm that PDS affects the degradation of an autophagy substrate, mHtt. BACHD mice express the full-length human mHtt gene and recapitulate multiple features of Huntington disease ([@bib32]). We cultured primary cortical neurons from BACHD mouse pups and treated them with a vehicle or PDS. mHtt levels were measured with western blotting. As expected, PDS treatment increased the levels of mHtt by twofold, indicating that degradation of mHtt is inhibited ([Figure 5---figure supplement 2a,b](#fig5s2){ref-type="fig"}). Actin was used as a loading control, as we previously found that the levels of the actin protein in neurons are not significantly affected by PDS ([@bib64]).

Next, we assessed whether G4 ligands regulate a specific form of autophagy, mitophagy, the autophagic degradation of mitochondria that depends on ATG7 ([@bib82]). To measure mitophagy in live neurons, we used an optical method that combines a pH-sensitive protein Keima with automated imaging. Keima is a fluorescent protein that changes both its excitation and emission spectra in response to environmental pH changes, emitting green light at neutral pH and red light at acidic pH. Mitochondrially targeted Keima has been successfully used to study mitophagy ([@bib40]; [@bib71]). Primary cortical neurons were transfected with mito-Keima and BFP, treated with a vehicle, PDS or BRACO19, and the red fluorescence intensity of mito-Keima was analyzed in individual neurons ([Figure 5f,g](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1c](#fig5s1){ref-type="fig"}). Similar to previous studies ([@bib14]), we found that basal mitophagy is a relatively slow process, with first mitochondria appearing in the lysosomes \~ 2 days after mito-Keima transfection, and that mitophagy is primarily localized to the neuronal soma ([Figure 5f,g](#fig5){ref-type="fig"}). In neurons treated with PDS, mitophagy efficiency was reduced by 0.6-fold compared to neurons treated with a vehicle ([Figure 5g](#fig5){ref-type="fig"}). Interestingly, the BRACO19 treatment reduced mitophagy by 0.8-fold, indicating that PDS and BRACO19 affect neuronal homeostasis differently. Thus, we conclude that, in primary cultured neurons, G4 stabilization downregulates autophagy, including mitophagy.

Finally, we wondered whether ectopic expression of ATG7 mitigates neurotoxicity and autophagy deficits induced by PDS. p62 or sequestosome-1 is a scaffolding protein that acts as an adaptor to identify and deliver cargo to the autophagosome for degradation ([@bib54]; [@bib41]). p62 is degraded together with the cargo, making p62 a commonly used autophagy marker. Two cohorts of cultured neurons were transfected with p62-GFP and mApple. The third neuronal cohort was transfected with p62-GFP and ATG7-mApple. mApple-expressing neurons were treated with a vehicle (control) or with PDS, neurons transfected with p62-GFP, and ATG7-mApple were treated with PDS (PDS+ATG7). We analyzed fluorescence intensity of p62-GFP and discovered that PDS-treated mApple-expressing neurons exhibited a 1.7-fold increase of p62-GFP fluorescence intensity over control neurons. Interestingly, ATG7-overexpressing neurons treated with PDS displayed 0.7-fold reduction of p62-GFP fluorescence intensity, indicating that overexpressing ATG7 mitigates the inhibitory effects of PDS on neuronal autophagy ([Figure 5---figure supplement 3a,b](#fig5s3){ref-type="fig"}). Similarly, ATG7 overexpression mitigates PDS-induced neurotoxicity ([Figure 5---figure supplement 3c](#fig5s3){ref-type="fig"}). These data further highlight the importance of ATG7 in neuronal autophagy and survival.

Mice treated with PDS develop memory deficits {#s2-5}
---------------------------------------------

We then wondered if PDS would have any effect on the brain in mice. Stabilizers of G4-DNA are being investigated as an anti-cancer therapy. In a prior in vivo study, a G4-binding small molecule (MM41) was used as an anti-cancer therapy with a dosage and schedule that was tolerated ([@bib67]). In our studies, we used a comparable dosage and schedule of PDS. In these experiments, we used old male and female mice (25 months). Mice were randomized and injected weekly with a vehicle or PDS for 8 weeks (4 mg/kg/week), and thereafter, these mice completed the novel object recognition (NOR) test, a standard test for recognition memory that assesses both hippocampal and cortical cognitive function ([@bib1]). The discrimination index measures the ability of the tested animal to differentiate a novel object from the familiar object, which was previously presented to the animal. Thus, higher discrimination index indicates if the animal is able to recognize the novel object. Male and female mice treated with PDS exhibited a reduced discrimination index, compared to vehicle-treated mice ([Figure 6a](#fig6){ref-type="fig"}). These were old mice and even vehicle-treated mice were expected to exhibit significant age-associated neuropathology. We analyzed one of the hallmarks of aging and downregulated autophagy---the levels of lipofuscin---in male and female mice. Lipofuscin is a mixture of accumulated oxidized proteins and lipids found in aged brains ([@bib11]). Brains from PDS-treated mice contained more lipofuscin than vehicle-treated mice ([Figure 6b,c](#fig6){ref-type="fig"}), demonstrating that the treatment with PDS promotes aging phenotypes in the mouse brains. Our data also suggest that anticancer drugs that target G4-DNA may accelerate brain aging and lead to early dementia.

![Mice treated with PDS develop memory deficits and aged-related symptoms.\
(**a**) 25-month-old male and female mice were intraperitoneally injected with a solution of a vehicle in PBS (control, cont) or with a solution of PDS in PBS (5 mg/kg, PDS) once a week for 8 weeks. After treatment, mice were tested for short-term memory in the novel object recognition test and discrimination index (DI) was calculated. \*p-value(male-cont vs PDS)=0.0265, \*p-value(female-cont vs PDS)=0.0382, p-value(male vs female)=0.1029 (two-way ANOVA). Six mice per group were analyzed. (**b**) Mice were sacrificed, and their brains were analyzed for the lipofuscin autofluorescent age pigment. (**c**) Quantification of autofluorescence from (**c**). \*\*p-value(male-cont vs PDS)=0.0043, \*\*\*p-value(female-cont vs PDS)=0.0007, p-value(male vs female)=0.2121 (two-way ANOVA). Six mice per group were analyzed.](elife-52283-fig6){#fig6}

Brain samples from old mice contain stable G4-DNA {#s2-6}
-------------------------------------------------

Transcription of many genes is altered in the aged brain ([@bib56]), and many of these gene bodies or promoters contain PQFSes. For example, expression of *Atg7* decreases in the human brain during normal aging ([@bib53]). In yeast, flies, worms, and human immune and cancer cells, histone and chromatin modifications regulate *Atg7* expression ([@bib76]; [@bib21]; [@bib22]). We first analyzed the mRNA levels of *Atg7* in young and aged mice and observed that *Atg7* mRNA is downregulated by 25% in the aged brains compared to brain samples from young mice ([Figure 7a](#fig7){ref-type="fig"}). Second, we hypothesized that aged brains contain stable G4-DNA. To test that, we used the BG4 antibody, which recognizes G4 structures in fixed cytological samples ([@bib9]). Young (3 months old) and old (25 months old) mice were sacrificed, and their brains were analyzed by immunohistochemistry with the BG4 antibody. BG4-positive puncta were seen in aged mice and were very rarely seen in young mice ([Figure 7b,c](#fig7){ref-type="fig"}). These data suggest that the G4 landscape is modulated by aging in vivo, which opens new avenues for aging research.

![Brain samples from aged mice exhibit elevated levels of G4-DNA.\
3-month-old (young) and 25-month-old (old) mice were sacrificed, and their brains were processed for RT-qPCR and immunohistochemistry analysis. (**a**) Cortical brain samples from young and old mice were lysed, and mRNA was extracted. mRNA samples were retro-transcribed and analyzed for expression of the *Atg7* gene. \*\*p(young vs old)=0.0011 (t-test). Six mice per group were analyzed. (**b**) Brain samples from young and old mice were stained with antibodies against BG4 (green channel) and the Hoechst dye (nuclei marker, blue channel), and imaged with a fluorescent microscope. In the zoomed image, white arrows depict some G-quadruplex-positive structures in the nuclei. (**c**) Quantification of BG4 fluorescence intensity in the hippocampus (hip) and the cortex (cort) of young and old mice. \*\*\*p(hip-young vs old)=0.0001; \*\*\*p(cor-young vs old)=0.0001. n.s., non-significant, p(young-hip vs cor)=0.35 (one-way ANOVA). Six mice per group were analyzed.](elife-52283-fig7){#fig7}

Pif1 rescues PDS-induced phenotypes in cultured primary neurons {#s2-7}
---------------------------------------------------------------

More than 20 G4 helicases unwind G4-DNA, among which Pif1 is one of the most potent and studied ([@bib69]). Pif1 unwinds G4 structures even in the presence of G4 ligands ([@bib88]). Thus, we wondered whether Pif1 could rescue PDS-induced phenotypes in cultured primary neurons. Primary neurons were transfected either with GFP and mApple (a marker of viability and morphology) or with Pif1-GFP and mApple ([Figure 8a--d](#fig8){ref-type="fig"}). Loss of the mApple fluorescence is a sensitive marker of neuronal death ([@bib80]; [@bib79]; [@bib3]). Therefore, by analyzing when each neuron lost its fluorescence, we can measure neuronal survival with cumulative hazard statistics ([Figure 8e](#fig8){ref-type="fig"}). Transfected neurons were tracked longitudinally for several days. Surprisingly, Pif1-GFP was somewhat toxic for primary cortical neurons, in comparison with control GFP-expressing neurons ([Figure 8e](#fig8){ref-type="fig"}). Nevertheless, Pif1-GFP partially rescued PDS-associated neurotoxicity. Next, we tested if Pif1-GFP rescues autophagic deficits in cultured neurons exposed to PDS. Remarkably, Pif1-GFP reduced the half-life of Dendra2-LC3 by 0.6-fold in neurons treated with PDS ([Figure 8f](#fig8){ref-type="fig"}). We then used a mutant form of Pif1 without ATPase/helicase activity as a control. Expectedly, mutant Pif1 could not rescue PDS-associated autophagy reduction ([Figure 8f](#fig8){ref-type="fig"}). These data indicate that Pif1 likely activates coping mechanisms in degenerating neurons, leading to better autophagy.

![The helicase Pif1 restores autophagy in PDS-treated neurons.\
(**a**) An example of survival analysis. Cultured primary neurons were transfected with the red fluorescent protein mApple as a marker of cell morphology and viability. Neurons were longitudinally imaged each 24 hr for 6 days with an automated microscope. Each image is a montage of 25 individual non-overlapping images. Scale bar is 400 µm. (**b**) Zoomed images from (**a**) at each time point. Images demonstrate the ability to track the same group of neurons over time, and they show the progression of neuron development (note how neurites grow in the top-left neuron), and neurodegeneration (two neurons to the right side of the images gradually lose their neurites until they die). Scale bar is 40 µm. (**c**) Zoomed image that shows the complex neurite arborization of a depicted neuron from (**b**) 144 hr after transfection. Scale bar is 20 µm. (**d**) An example of a neuron co-transfected with mApple (red) and Pif1-GFP (green). Note that Pif1-GFP is mostly nuclear. (**e**) Two cohorts of cultured primary neurons were co-transfected with mApple (as a morphology and survival marker) and GFP (as a control construct), and other two cohorts of neurons were co-transfected with mApple and Pif1-GFP. One cohort of neurons co-transfected with mApple and GFP was treated with a vehicle (Apple), and the second one with 0.5 μM PDS. Another cohort of neurons co-transfected with mApple and Pif1-GFP was treated with a vehicle (Pif1), and the second one with 0.5 μM PDS (Pif1+PDS). Neurons were longitudinally imaged during 4 days, and risks of death were analyzed. \*\*\*p=0.0001 (log-rank test). Results were pooled from three independent experiments. (**f**) Two cohorts of cultured primary neurons were co-transfected with Dendra2-LC3 and GFP (as a control construct), and other two cohorts of neurons were co-transfected with Dendra2-LC3 and Pif1-GFP. One cohort of neurons co-transfected with Dendra2-LC3 and GFP was treated with a vehicle (control, cont), and the second one with 0.1 μM PDS (PDS). Also, one cohort of neurons co-transfected with mApple and Pif1-GFP was treated with a vehicle (Pif1), and the second one with 0.1 μM PDS (Pif1+PDS). One last cohort of neurons was transfected with mApple and mutant Pif1-GFP and treated with PDS (mPif1+PDS). Neurons were longitudinally imaged, and the half-life of Dendra2-LC3 of each group was analyzed, and normalized to one with respect to the control group. \*\*p(cont vs PDS)=0.001, \*\*p(PDS vs Pif1+PDS)=0.001, p(Pif1 vs Pif1+PDS)=0.001. n.s., non-significant, p(cont vs Pif1)=0.1726, p(cont vs Pif1+PDS)=0.3239, p(PDS vs mPif+PDS)=0.4267 (one-way ANOVA). One hundred neurons per group were analyzed from two independent experiments.](elife-52283-fig8){#fig8}

Discussion {#s3}
==========

In this study, we demonstrated that the levels of *Atg7* and, therefore, neuronal autophagy are downregulated by the G4-ligands PDS and BRACO19. We showed that a PQFS identified in the *Atg7* gene can fold into a G4 structure, as demonstrated by spectroscopy (CD, TDS and NMR), which interacts with PDS and BRACO-19, the HF2 antibody, and the G4-binding protein PC4. Mice treated with PDS exhibited memory deficits and accumulation of lipofuscin. Importantly, we discovered that aged mouse brains contain numerous G4-DNA, while young brains have very few. Our data suggest that an age-associated change in DNA conformation could be a novel epigenetic-like mechanism of gene expression in aging neurons ([@bib42]).

There is a good consensus in the autophagy field that autophagy plays a positive role in slowing aging and increasing longevity ([@bib37]). Autophagy-related genes are critical for longer healthspan and lifespan extension in worms, flies, and mice ([@bib37]). Mice with enhanced basal autophagy have increased healthspan and lifespan ([@bib24]). A decrease in autophagic activity leads to the accumulation of damaged and senescent cellular components in almost all cell types of aging organisms ([@bib17]). Transcription factors, such as TFEB and FOXO, regulate the expression of many autophagy genes involved in the healthspan and lifespan ([@bib52]). We previously demonstrated that transcription factors Nrf2 and TFEB positively regulate neuronal autophagy and promote basal neuronal survival and survival of neurons under stress ([@bib81]; [@bib63]). Epigenetic histone and chromatin modifications also regulate autophagy during aging ([@bib52]; [@bib5]). For example, autophagy genes can be epigenetically silenced ([@bib5]; [@bib4]). Conversely, pharmacologic inhibition or genetic downregulation of histone methyltransferase G9a leads to the activation of autophagy in cancer cells and in fibroblasts ([@bib4]). The expression of many critical autophagic genes, such as *Atg5* and *Atg7,* decreases with aging ([@bib53]; [@bib56]). Many of these genes contain PQFS motifs in their introns, exons or promoters. Our findings indicate that G4-DNA may play crucial roles in transcription of autophagic genes in aged neurons.

A link between G4-DNA ligands and autophagy has already been demonstrated in cancer cells. Мelanoma cells stop dividing and upregulate autophagy when treated with the G4 ligand Ant1,5 ([@bib68]). In agreement with this study, a G4 agent, SYUIQ-5, inhibits proliferation, damages G4-DNA enriched telomeres, and upregulates autophagy in CNE2 and HeLa cancer cells ([@bib87]). The G4 ligand 20A causes cell growth arrest and upregulates autophagy in HeLa cells ([@bib7]). In our work, however, we found that, in neurons, G4-ligands trigger opposite effects, downregulating autophagy in post-mitotic neurons, which comes with no surprise as the autophagic pathways in neurons differ from those in other cell types ([@bib45]).

G4-DNA-associated regulation of transcription extends well beyond the autophagy genes. We recently demonstrated that PDS and BRACO19 downregulate the *Brca1* gene in cultured primary neurons---the Brca1 gene and gene's promoter contain G4-DNA motifs---leading to DNA damage ([@bib64]). Ectopically increasing BRCA1 levels attenuates DNA damage associated with PDS treatment, indicating that *Brca1* downregulation impedes DNA damage repair and DNA double strand breaks accumulate as a result. Age-dependent accumulation of stabilized G4-DNA structures in diverse genes may lead to neuronal senescence and, eventually, to neurodegeneration. In some neurodegenerative diseases and in advanced aging, neurons exhibit various DNA/chromatin abnormalities, including aneuploidy and transposable element dysregulation ([@bib66]; [@bib26]; [@bib78]). Our findings suggest that age-dependent changes in DNA conformation and accumulation of G4-DNA could represent a novel mechanism of senescence that includes the autophagic and non-autophagic genes in general. Future studies will determine the exact G4-DNA loci in neurons, how these loci differ between neuronal cell types (*e.g.,* cortical versus granular cerebellar), and how these loci change as neurons develop and age.

G4-DNA structures fold spontaneously within single-stranded DNA (ssDNA) transiently formed during DNA replication, and helicases (including Pif1) unfold them ([@bib74]). A similar process occurs during transcription on ssDNA in a transcriptional bubble, and Pif1 dismantles these G4-DNA structures as well ([@bib74]). G4-RNA structures being mostly protein bound form only transiently in living cells ([@bib23]; [@bib85]). Post-mitotic neurons do not divide, and so, G4 ligands may have a strong effect on co-transcriptionally formed G4-DNA and G4-RNA. In our current and previous studies ([@bib64]), we observed no significant accumulation of mRNA (*Atg7* and *Brca1* [@bib64]) in PDS-treated neurons (*e.g.,* G4-RNA), suggesting that mRNA stability is not considerably affected by G4 ligands. Therefore, in post-mitotic neurons, the primary target of G4-ligands would likely be transcription. Nevertheless, we cannot exclude a possibility that PDS may affect RNA metabolism by stabilizing G4-RNA. Intriguingly, we found that PDS downregulates *Atg7* stronger than BRACO19, indicating that these two ligands have different affinities towards the G4 structures in living neurons or/and bind to different G4-DNA conformations. As neurons are highly specialized cells, they may have their own, unique G4-DNA pathways, which may be drastically different from G4-DNA mechanisms in non-neuronal cells.

Pif1 is a class of nuclear and mitochondrial 5\'−3\' DNA helicases present in all eukaryotes ([@bib59]). Originally identified in yeast as an important factor for maintaining mitochondrial DNA ([@bib51]), Pif1's functions now include the regulation of telomere length, replication, and resolving G4-DNA ([@bib13]). Among G4-DNA helicases, Pif1 is one of the most potent and can unwind G4-DNA stabilized by G4-DNA-interacting small molecules ([@bib69]; [@bib88]). We demonstrate that Pif1 rescues phenotypes associated with PDS treatment. Intriguingly, expression of Pif1 itself somewhat upregulates autophagy. Therefore, in addition to histone acetyltransferases facilitating chromatin decondensation and promoting the expression of autophagy-related genes ([@bib52]; [@bib5]), Pif1 may also help to sterically allow the transcriptional machinery to transcribe DNA, including autophagic and non-autophagic genes. Nevertheless, we cannot fully exclude a possibility that Pif1 is protective in our experiments with PDS due to unknown functions besides being a G4-DNA helicase. Intriguingly, prior in vitro studies found that Pif1's G4-DNA unwinding activity is diminished by G4 ligands (*e.g.,* PDS), which appears to contradict to our in vivo findings. Nevertheless, the relevance of these data to our study is not straightforward since a G4-DNA forming sequence was used without its complementary sequence in the in vitro studies. Adding the complementary DNA sequence unfolds the G4-DNA/ligand complexes ([@bib59]). In addition, the in vitro experiments assayed the activity of Pif1 using an excess of G4 ligands ([@bib59]), and therefore, the data are not easy to extrapolate to our neuronal in vivo model. Also, in our studies with living neurons, Pif1 was overexpressed before PDS was added to the media, and thus, the kinetics of Pif1-G4-DNA-PDS interactions may be overly complex for a direct comparison to the in vitro conditions.

Our findings have important ramifications for aging and neurodegeneration research. We and others previously demonstrated that neuronal autophagy can be targeted therapeutically to mitigate or potentially stop neuronal aging and neurodegeneration. In this study, we demonstrate that there is a novel layer of autophagy regulation -- G4-DNA. Our data suggest that G4-DNA and G4-DNA-regulating proteins might be promising therapeutic targets for developing therapies against age-associated neurodegenerative disorders.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                   Designation                                                                             Source or\                   Identifiers                                                                      Additional\
  (species) or\                                                                                                                           reference                                                                                                     information
  resource                                                                                                                                                                                                                                              
  ----------------------------------------------- --------------------------------------------------------------------------------------- ---------------------------- -------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  Gene (Rattus norvegicus)                        ATG7                                                                                    N/A                          Gene-NCBI: ID: NC_005103.4                                                       

  Strain, strain background (*Mus musculus*)      C57BL/6                                                                                 Jackson Laboratoy            664                                                                              female and male

  Strain, strain background (Rattus norvegicus)   Long Evans                                                                              Charles River                6                                                                                N/A

  Cell line (Rattus norvegicus)                   primary cortical neurons                                                                                                                                                                              Neurons isolated from Long-Evans rat embryos (E17--18) cortices

  Antibody                                        anti-microubule-associated protein 1 light chain three alpha (LC3; rabbit polyclonal)   MBL                          \#PD014                                                                          (1:1000), overnight 4°C

  Antibody                                        anti-atg7 (clone D12B11; rabbit monoclonal)                                             Cell Signaling               \#8558                                                                           (1:1000), overnight 4°C

  Antibody                                        anti-beta actin (clone 8H10D10; mouse monoclonal)                                       Cell Signaling               \#3700                                                                           (1:2000), overnight 4°C

  Antibody                                        anti-DYKDDDDK Tag (FLAG; clone D6W5B; rabbit polyclonal)                                Cell Signaling               \#2368                                                                           (1:500), overnight 4°C

  Antibody                                        anti-microtubule-associated protein-2 (MAP-2; clone A-4; mouse monoclonal)              Santa Cruz Biotechnology     \#sc-74421                                                                       (1:500), overnight 4°C

  Antibody                                        anti-rabbit-HRP                                                                         EMD Millipore                \#AP307P                                                                         (1:2000), overnight 4°C

  Antibody                                        anti-mouse-HRP                                                                          EMD Millipore                \#AP308P                                                                         (1:2000), overnight 4°C

  Antibody                                        anti-mouse Alexa Fluor-488                                                              Life Technologies            \#A11001                                                                         (1:500), overnight 4°C

  Antibody                                        anti-Huntingtin protein (Htt; clone mEM48; mouse monoclonal)                            EMD Millipore                \#MAB5374                                                                        (1:1000), overnight 4°C

  Antibody                                        anti-rabbit Alexa Fluor-546                                                             Life Technologies            \#A11010                                                                         (1:500), overnight 4°C

  Antibody                                        anti-HF2                                                                                ([@bib55])                                                                                                    (1:100), overnight 4°C, prepared in Nayun Kim's lab

  Antibody                                        anti-BG4                                                                                ([@bib9])                                                                                                     (1:100), overnight 4°C, prepared in Nayun Kim's lab

  Recombinant DNA reagent                         lipofectamine 2000                                                                      Thermo Fisher Scientific     12566014                                                                         

  Recombinant DNA reagent                         pCAG-TagBFP                                                                             VectorBuilder                pRP\[Exp\]-CAG \> TagBFP                                                         

  Recombinant DNA reagent                         pCAG-EGFP-hPIF1                                                                         VectorBuilder                pRP\[Exp\]-CAG \> EGFP(ns): hPIF1\[ORF026999\]                                   

  Recombinant DNA reagent                         pCAG-EGFP-mutant hPIF1                                                                  VectorBuilder                pRP\[Exp\]-CAG \> EGFP(ns):{hPIF1\[ORF026999\]\*(E307Q)}                         

  Recombinant DNA reagent                         EF1A-mApple-ATG7                                                                        VectorBuilder                pRFP\[Exp\]-EF1A \> mApple(ns):mAtg7\[NM_001253717.1\]                           

  Recombinant DNA reagent                         pSANG10-3F-BG4                                                                          Addgene                      \#55756; deposited by Dr. Shankar Balasubramanian, the University of Cambridge   

  Recombinant DNA reagent                         pGW1-Dendra2-LC3                                                                        ([@bib81])                                                                                                    

  Recombinant DNA reagent                         Httex1-Q46-Dendra2                                                                      ([@bib81])                                                                                                    

  Recombinant DNA reagent                         pGW1-mito-Keima                                                                         other                                                                                                         It was cloned from the mt-mKeima/pIND(SP1) construct that we kindly received from Dr. Atsushi Miyawaki (RIKEN Brain Science Institute, Japan)

  Sequence-based reagent                          ATG7, forward                                                                           Lone Star laboratories       5'-TCCTGAGAGCATCCCTCTAATC-3'                                                     

  Sequence-based reagent                          ATG7, reverse                                                                           Lone Star laboratories       5'- CTTCAGTTCGACACAGGTCATC-3'                                                    

  Sequence-based reagent                          TBP, forward                                                                            Lone Star laboratories       5'-AGTGCCCAGCATCACTGTTT-3'                                                       

  Sequence-based reagent                          TBP, reverse                                                                            Lone Star laboratories       5'-GGTCCATGACTCTCACTTTCTT-3'                                                     

  Sequence-based reagent                          ATG2700                                                                                 Dr. Monchaud lab.            ATTCTTGGGGCTGGGGTCCCT TGGGGAACTGTATTGGGTGAACC                                    

  Sequence-based reagent                          SS-DNA                                                                                  Dr. Monchaud lab.            GCACGCGTATCTTTTTGGCGCAGGTG                                                       

  Commercial assay or kit                         RNeasy Mini kit                                                                         Qiagen                       74104                                                                            

  Commercial assay or kit                         iScript Reverse Transcription SuperMix                                                  BioRad                       1708840                                                                          

  Chemical compound, drug                         Pyridostatin (PDS)                                                                      Cayman Chemical              18013                                                                            

  Chemical\                                       10-(4′-(N-diethylamino)butyl)−2-chlorophenoxazine (10-NCP)                              EMD Millipore                925681--41                                                                       
  compound, drug                                                                                                                                                                                                                                        

  Chemical compound, drug                         N-TASQ                                                                                  ([@bib49]; [@bib50])                                                                                          synthesized by Dr. David Monchaud

  Software, algorithm                             JMP software                                                                            SAS Institute, Houston, TX                                                                                    

  Other                                           Hoechst dye                                                                             Santa Cruz Biotechnology     sc-394039                                                                        

  Other                                           poly-D-lysine                                                                           Millipore                    A-003-E                                                                          

  Other                                           Neurobasal Medium                                                                       Life Technologies            21103--049                                                                       

  Other                                           B-27                                                                                    Life Technologies            17504--044                                                                       

  Other                                           GlutaMAX                                                                                Life Technologies            35050--061                                                                       

  Other                                           penicillin-streptomycin                                                                 Life Technologies            15240.062                                                                        

  Other                                           HisPur Ni-NTA resin                                                                     Thermo Scientific            88221                                                                            

  Other                                           Dynabeads                                                                               ThermoFisher Scientific      10002D                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chemicals and plasmids {#s4-1}
----------------------

PDS was from Cayman Chemical (\#18013). 10-NCP (10-(4′-(N-diethylamino)butyl)−2-chlorophenoxazine) was from EMD Millipore ((\#925681--41). Hoechst dye was from Santa Cruz Biotechnology (\#sc-394039). N-TASQ was synthesized as described ([@bib49]; [@bib50]; [@bib84]). Antibodies against LC3 were from MBL (\#PD014). Antibodies against ATG7 (D12B11; \#8558), β-actin (8H10D10; \#3700), and the Anti-FLAG DYKDDDDK M2 tag (D6W5B; \#2368) were from Cell Signaling. Mouse antibodies against MAP2c (A-4, \#sc-74421) were from Santa Cruz Biotechnology. Antibodies against Htt (mEM48), rabbit IgG(H+L) conjugated with horseradish peroxidase (HRP) (\#AP307P), and mouse IgG(H+L) conjugated with HRP (\#AP308P) were from EMD Millipore. Anti-mouse Alexa Fluor 488-labeled (\#A11001) and anti-rabbit Alexa Fluor 546-labeled (\#A11010) secondary antibodies were from Life Technologies. A single-chain BG4 antibody that recognizes G4 structures ([@bib9]) was purified in the lab of Dr. Nayun Kim. pGW1-Dendra2-LC3 was described ([@bib81]). pGW1-mito-Keima was cloned from the mt-mKeima/pIND(SP1) construct that was received from Dr. Atsushi Miyawaki (RIKEN Brain Science Institute, Japan). pCAG-TagBFP, pCAG-EGFP-PIF1, pCAG-EGFP-mPIF1 (E307Q [@bib31]), and pEF1A-mApple-ATG7 were cloned by VectorBuilder.

Cell cultures and transfection {#s4-2}
------------------------------

Cortices from rat embryos (E17--18) were dissected, dissociated, and plated on 24-well tissue-culture plates (4 × 10^5^/well) coated with poly-D-lysine (BD Biosciences, San Jose, CA), as described ([@bib64]; [@bib62]; [@bib65]). Primary cortical neurons were grown in Neurobasal Medium (Life Technologies, Carlsbad, CA) supplemented with B-27 (Life Technologies), GlutaMAX (Life Technologies) and penicillin-streptomycin (Life Technologies). Primary cultures were transfected with Lipofectamine2000 (Thermo Fisher Scientific) and a total of 1--2 μg of plasmid DNA per well, as described ([@bib64]; [@bib62]; [@bib65]).

Survival analysis {#s4-3}
-----------------

We used automated microscopy and longitudinal analysis to determine neuronal survival. This method allows us to track large cellular cohorts and to sensitively measure their survival with the statistical analyses used in clinical medicine ([@bib62]; [@bib79]; [@bib3]). For tracking the same group of cells over time, an image of the fiduciary field on the plate was collected at the first time-point and used as a reference image. Each time the same plate was imaged, the fiduciary image was aligned with the reference image. Neurons that died during the imaging interval were assigned a survival time. These events were transformed into log values and plotted in risk of death curves and analyzed for statistical significance (log-rank test). JMP software (SAS Institute, Houston, TX) was used to analyze data and generate survival curves ([@bib80]; [@bib81]).

Optical pulse-chase {#s4-4}
-------------------

Photoswitching of Dendra2-LC3 and Htt^ex1^-Q~46~-Dendra2 was performed as described ([@bib6]; [@bib81]; [@bib62]). Upon brief irradiation with short-wave visible light, Dendra2 undergoes an irreversible conformational change ('photoswitch'). The spectral properties of Dendra2 then change from that of a protein that absorbs blue light and emits green fluorescence to that of one that absorbs green light and emits red fluorescence ([@bib6]). Photoswitched Dendra2 maintains these spectral properties until the cell degrades the protein. The red fluorescence intensities from a region of interest in individual cells were measured at different time points. Fluorescence of non-photoswitched 'green' molecules served as a guide for drawing the region of interest. The decays of red fluorescence were plotted against time, transformed into log values, and individual half-life (t~1/2~) was analyzed ([@bib6]; [@bib81]). The half-lives (H^1/2^) of Dendra2-LC3 was calculated using the formula: H^1/2^ = (24xLn(2))/(Ln(A/A°). A = final fluorescence; A°=initial fluorescence.

Immunoblotting {#s4-5}
--------------

Neuronal cultures were lysed in RIPA buffer (150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris/HCl (pH 8.0), with phosphatase and protease inhibitors cocktail) on ice. Lysates were vortexed and cleared by centrifugation (14000 g, 10 min, 4°C). Supernatants were collected, and protein concentrations were determined by the Bicinchoninic Acid Protein Assay Kit (Thermo Scientific). Samples were analyzed by SDS/PAGE (4--12% gradient gels), and proteins were transferred on to nitrocellulose membranes using the iBlot2 system (Life Technologies). Membranes were blocked with 5% skimmed milk for 1 hr at room temperature, and they were incubated with the primary antibodies (anti-LC3, Htt, anti-actin or anti-ATG7) overnight at 4°C. Membranes were then washed with TBS (Tris-buffered saline; 10 mM Tris/HCl and 150 mM NaCl (pH 7.4)) and incubated with anti-rabbit-HRP or anti-mouse-HRP for 1 hr at room temperature. Chemiluminescent signal was visualized with Prometheus ProSignal Pico (Genesee Scientific) on Blue Devil autoradiography films (Genesee Scientific).

G4-DNA analyses {#s4-6}
---------------

The QGRS mapper (<http://bioinformatics.ramapo.edu/QGRS/index.php>) was used to determine the potential G4-DNA structures contained in genes of interest and their G-scores. Search parameters: maximal length: 45; minimal G-group size: 3; loop size: from 0 to 10^2^.

RNA extraction and qRT-PCR {#s4-7}
--------------------------

Total RNA was extracted from primary culture using the RNeasy Mini kit (\#74104, Qiagen), and then reverse transcribed using iScript Reverse Transcription SuperMix (\#1708840, Bio-Rad), according to the manufacturer's protocol and as described ([@bib64]). RT-qPCR was performed using a Bio-Rad CFX96 Touch machine using SSoAdvanced Universal SYBR Green (\#1725275, Bio-Rad) for visualization and quantification according to the manufacturer's instructions. Primer sequences were: ATG7 (*Atg7*), forward: 5′-TCCTGAGAGCATCCCTCTAATC-3′, reverse: 5′- CTTCAGTTCGACACAGGTCATC-3′; TBP (*Tbp*), forward: 5′-AGTGCCCAGCATCACTGTTT-3′, reverse: 5′-GGTCCATGACTCTCACTTTCTT-3′. The PCR conditions were: 95°C for 3 min, followed by 40 cycles of 95°C for 10 s and 55°C for 30 s. Relative expression levels were calculated from the average threshold cycle number using the delta-delta Ct method.

Oligonucleotides {#s4-8}
----------------

The sequences of oligonucleotides used herein were: Atg7-32, 5′-GGGGCTGGGGTCCCTTGGGGAACTGTATTGGG-3′; mutAtg7-32, 5′-GCGCCTGCGCTCCCTTGCGCAACTGTATTGCG-3′; fam-Atg7-32-tamra, 5′-*fam*-GGGGCTGGGGTCCCTTGGGGAACTGTATTGGG-*tamra*-3′; fam-mutAtg7-32-tamra: 5′-*fam*-GCGCCTGCGCTCCCTTGCGCAACTGTATTGCG-*tamra*-3′. The lyophilized DNA strands purchased from Eurogentec (Seraing, Belgium) were firstly diluted at 500 µM in deionized water (18.2 MΩ.cm resistivity). DNA samples were prepared in a Caco.K10 buffer, composed of 10 mM lithium cacodylate buffer (pH 7.2) plus 10 mM KCl/90 mM LiCl. Samples were prepared by mixing 40 µL of the constitutive strand (500 µM) with 8 µL of a lithium cacodylate buffer solution (100 mM, pH 7.2), plus 8 µL of a KCl/LiCl solution (100 mM/900 mM) and 24 µL of water. The actual concentration of each sample was determined through a dilution to 1 µM theoretical concentration *via* a UV spectral analysis at 260 nm (after 5 min at 90°C) with the following molar extinction coefficient (ε) values: 302000 (Atg7-32), 276500 (mutAtg7-32), 355300 (fam-Atg7-32-tamra) and 329800 l.mol^−1^.cm^−1^ (fam-mutAtg7-32-tamra). The G4 structures were folded heating the solutions at 90°C for 5 min, and then cooling them on ice (for 7 hr) before being stored overnight at 4°C.

CD and TDS experiments {#s4-9}
----------------------

CD and UV-Vis spectra were recorded on the JASCO J-815 spectropolarimeter and the JASCO V630Bio spectrophotometer, respectively, in a 10 mm path-length quartz semi-micro cuvette (Starna). CD spectra of 3 μM of Atg7-32 and mutAtg7-32 (Eurogentec) were recorded over a range of 220--340 nm (bandwidth = 1 nm, 1 nm data pitch, 1 s response, scan speed = 500 nm.min^−1^, averaged over five scans) without and with dehydrating agent (PEG200, 20% v/v; acetonitrile, 50% v/v) in 600 μL (final volume) of in 10 mM lithium cacodylate buffer (pH 7.2) plus 10 mM KCl and 90 mM LiCl (Caco.K10). Final data were treated with OriginPro8, zeroing CD spectra at 340 nm. TDS experiments were performed with Atg7-32 and mutAtg7-32 (3 μM) recording the optical over a range of 220--340 nm at 20°C and 80°C in 600 μL (final volume) of Caco.K10. Final data were treated with Excel (Microsoft Corp.) and OriginPro9.1 (OriginLab Corp.). TDS signature were calculated subtracting the spectra collected at 20°C from the spectra collected at 80°C, normalized (0 to 1) and zeroed at 340 nm.

FRET-melting experiments {#s4-10}
------------------------

Experiments were performed in a 96-well format using a Mx3005P qPCR machine (Agilent) equipped with FAM filters (λ~ex~ = 492 nm; λ~em~ = 516 nm) in 100 μL (final volume) of Caco.K10 with 0.2 μM of Fam-Atg7-32-Tamra or Fam-mutAtg7-32-Tamra (Eurogentec) with 0, 1, 2 and 5 molar equivalents of PDS and BRACO-19 (*i.e.*, 0, 0.2, 0.4 and 1.0 μM ligand). After a first equilibration step (25°C, 30 s), a stepwise increase of 1°C every 30 s for 65 cycles to reach 90°C was performed, and measurements were made after each cycle. Final data were analyzed with Excel (Microsoft Corp.) and OriginPro9.1 (OriginLab Corp.). The emission of FAM was normalized (0 to 1), and T~1/2~ was defined as the temperature for which the normalized emission is 0.5; ΔT~1/2~ values, calculated as follows: ΔT~1/2~ = \[T~1/2~(DNA+ligand)-(T~1/2~(DNA alone)\], and are means of three experiments.

NMR experiments {#s4-11}
---------------

Atg7-32 and mutAtg7-32 (Eurogentec) were annealed at 200 μM in a Caco.K10 by heating at 95°C for 10 min. The samples were cooled to 4°C (ice bath) and equilibrated at 4°C for at least 24 hr. ^1^H-NMR spectra (250 μL final volume) were acquired after the addition of DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) as internal calibration standard. NMR spectra were recorded at 298 K (4248 scans) using a 600 MHz Bruker Avance III HD spectrometer equipped with a cryogenic probe. Water suppression was achieved using excitation sculpting (pulse program: zgesgp). Final data were analyzed with TopSpin v4.0.6 (Bruker).

HF2 binding assay {#s4-12}
-----------------

HF2 antibody expression and purification were carried out as described ([@bib25]). The expression of the HF2 single--chain antibody was then induced by 100 mM isopropyl β-D-1-thiogalactopyranosid in *E. coli*. Cells were pelleted and resuspended in a lysis buffer (25 mM Tris-HCl, 100 mM NaCl, 10% glycerol, 1% NP-40 and 10 mM imidazole) and sonicated using the QSONICA sonicator. Purification of the 6XHis-tagged HF2 antibody was carried out using HisPur Ni-NTA resin according to the manufacturer's instruction (Thermo Scientific). The eluted protein was concentrated with the Amicon Ultra-4 Centrifugal Filter and stored at −20°C in 50% glycerol. For the binding assay, 5′- Cy5-labeled oligonucleotides (Sigma) were resuspended in 10 mM Tris-Cl containing 100 mM LiCl or KCl and denatured at 95°C for 5 min and then slowly cooled overnight to allow secondary structure formation. Annealed oligonucleotides were mixed with the purified HF2 antibody in 100 mM LiCl or KCl, 20 mM HEPES pH 7.5, 0.01% NP40, 5% glycerol, 5 mM MgCl~2~, and incubated at room temperature for 15 min before running on a 10% non-denaturing TBE-polyacrylamide gel with 0.5X TBE. Gel images were captured using the BioRad Chemidoc imager. Sequences of the oligonucleotides were:

1.  ATG2700, ATTCTTGGGGCTGGGGTCCCTTGGGGAACTGTATTGGGTGAACC

2.  SS-DNA, GCACGCGTATCTTTTTGGCGCAGGTG

DNA-dynabeads affinity purification of proteins {#s4-13}
-----------------------------------------------

DNA-Dynabeads affinity purification of proteins was carried out as described ([@bib30]) with several modifications. For DNA-conjugated Dynabeads preparation, biotinylated oligonucleotides ATG-2700 and SS-DNA were ordered from Sigma. The oligonucleotides were incubated at 60°C overnight in the presence of 10 mM Tris pH 7.5 and 100 mM KCl and then conjugated to Streptavidin-Coupled M-280 Dynabeads (Life Technologies) as per the manufacturer's instructions. Yeast extract was made by glass bead-mediated cell disruption in 2 ml of lysis buffer (50 mM HEPES--NaOH, pH 7.5, 300 mM KCl, 1 mM EDTA, 10% glycerol, 0.05% NP-40, 1 mM DTT, 1 mM PMSF, 1X protease inhibitor cocktail (Roche)). After mechanical lysis of cells with Biospec Mini-bead-beater, the cell lysate was collected in a 15 ml tube and sonicated. DNA-conjugated Dynabeads were washed once with the lysis buffer and incubated overnight with gentle inversion with the remaining yeast extract at 4°C. The beads were washed with the lysis buffer five times and then eluted by boiling in 1XSDS-PAGE loading buffer followed by immunoblotting analysis with the anti-FLAG (Sigma; \# A8592) or anti-His (Sigma; \# H1029) antibodies.

Fluorescence microscopy {#s4-14}
-----------------------

Live cell and fixed cell imaging was performed with the EVOS FL Auto Imaging System (Thermo Fisher Scientific). Lipofuscin was measured in the brain samples acquired from the aged female and male mice treated with a vehicle or with PDS (5 mg/kg). Brain samples were mounted on the glass slides and stained with the nuclear Hoechst dye. Samples were then imaged using the green GFP filter for autofluorescent lipofuscin and the blue DAPI filter with the EVOS microscopy system.

Immunocytochemistry {#s4-15}
-------------------

Cultured primary cortical neurons on coverslips were treated with a vehicle or with PDS overnight, fixed with 4% paraformaldehyde, permeabilized with a 0.5% Triton X-100/PBS solution, and blocked with a 5% bovine serum albumin/PBS solution. Neurons were then stained with antibodies against MAP2c and with the G4-selective fluorophore N-TASQ overnight. Neurons were incubated with secondary antibodies, stained with Hoechst dye, and imaged with the EVOS microscopy system.

Immunohistochemistry {#s4-16}
--------------------

To determine and analyze G4 quadruples in brain samples from young and aged mice, frozen floating brain sections were incubated with antibodies against G4 (BG4) overnight. Samples were then incubated with antibodies against FLAG for 1 hr at room temperature, and then with secondary antibodies conjugated with a fluorochrome for 1 hr at room temperature. Nuclei were stained with Hoechst dye. Brain sections were mounted on glass slides, and imaged with a Leica DM8i SPE confocal microscope or the EVOS microscope.

Novel object recognition test (NORT) {#s4-17}
------------------------------------

The test is a standard test for recognition memory that is sensitive to aging. For this test, we used old male and female mice (25 months). During the test, two identical objects were presented to each mouse in an arena, and the mice allowed to explore the objects for 10 min. The objects and their position in the arena will be pseudo-randomized between the different mice. After 1 hr interval, one of these objects was replaced with a novel object; again, the mouse was allowed to explore the objects for 10 min. We video recorded the behavior of mice and evaluated the differences in the exploration time with novel and familiar objects. The discrimination index (DI) was calculated as: DI=(TN\*100)/(TN+TF). TN is the time mouse spent exploring the novel object. TF is the time mouse spent exploring the familiar object. All test were performed by an investigator blinded to treatment group.

Statistical analysis {#s4-18}
--------------------

For longitudinal survival analysis, neurons that died during the imaging interval were assigned a survival time (the period between transfection and their disappearance from an image). These event times were used to generate exponential cumulative survival curves in JMP statistical software. Survival curves describe the risk of death for single cells in the group being longitudinally imaged. To determine differences in the survival curves, they were then analyzed for statistical significance by the log-rank test as described ([@bib64]; [@bib62]; [@bib65]). To compare differences across two groups, the groups were analyzed with Student's t-test. Differences across multiple groups were analyzed with one-way ANOVA.
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**Decision letter after peer review:**

\[Editors' note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.\]

Thank you for submitting your work entitled \"A small molecule G-quadruplex stabilizer reveals a novel pathway of autophagy regulation in neurons\" for consideration by *eLife*. Your article has been reviewed by a Senior Editor, a Reviewing Editor, and three reviewers. The reviewers have opted to remain anonymous.

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered at this moment for publication in *eLife*. However, we believe that this is a very interesting study that after further work would be appropriate for *eLife*. It reveals that G4 may represent a new putative intervention point to interfere with autophagy-related neurodegeneration represents an important discovery and that the implication of G4-DNA in autophagy and age-related neurological deficit is novel and will be of interest to a broad readership and of interest for *eLife*. We would invite to resubmit a properly revised version attending the comments of the three reviewers accompanying your submission with a rebuttal explaining point-by-point the comments of the reviewers.

Reviewer \#1:

Summary:

The G-quadruplex (G4) ligand pyridostatin (PDS) was found to downregulate expression of the Atg7 gene in neurons. The first intron of the Atg7 gene contains predicted G4-forming sequence that was indeed shown to form G4 and interact with PDS. Consistent with these findings, in vitro a G4 antibody and G4-binding protein bind to the Atg7 intron G4-sequence. In vivo, mice treated with PDS were found to develop memory deficits and accumulation of lipofuscin, a mixture of oxidized lipids and proteins previously observed to accumulate in aged brains. Brain samples from aged mice, but not young mice, contained G4 DNA, as evidenced by staining with G4-selective reagent. Overexpression of the G4-resolving helicase Pif1 in neurons improved phenotypes associated with PDS treatment, i.e., neuronal death. Based on their findings, the authors conclude that G4 DNA is involved in regulating autophagy in neurons.

Critical Comments:

\- The narrative of the Results section is noticeably deficient in making quantitative statements relating to the experimental data. This issue should be addressed throughout the Results section.

\- A useful control in the Pif1 rescue experiments would have been to test if a site-directed ATPase/helicase-dead mutant version of Pif1 failed to affect PDS-induced phenotypes in cultured primary neurons.

\- Please define/explain Dendra2-LC3 half-life and how it is a reliable indicator of autophagy. It is mentioned in Figure 4 that LC3 is an autophagy marker. This should be better described in Results section and reference(s) provided.

\- Aside from short-term memory as assayed by novel object recognition test, are there any other effects on mice treated with PDS in terms of development of memory deficits or neurological function/capacity? Were there any sex-specific effects?

\- The authors briefly mention in the Introduction the recently published paper by Beauvarlet et al., (April 2019) suggesting that G4 DNA in autophagic genes regulates autophagy in cancer cells. As cite in that work, there were several other previously published papers suggesting a connection of autophagy to G4 nucleic acid metabolism as probed by G4 ligands: Orlotti et al., (2012); Zhou et al., (2009); Zhou et al., (2009). While all these papers delved more into the relationships of G4 and autophagy in cancer, it would be useful to discuss these works in a single paragraph in the Discussion and place the current work in light of those findings.

\- In the Introduction, references should be provided for the statement that G4 has been implicated in neurodegenerative disorders frontotemporal dementia and ALS.

\- In previous work by the authors, they reported that PDS promotes DNA damage and downregulates transcription of BRCA1 in neurons (Aging (2017)). The showed that overexpressed BRCA1 mitigates PDS-induced DNA damage. Similarly, in the current work does overexpression of ATG7 enzyme modulate the PDS-related phenotypes observed? Is DNA damage accumulation in neurons also observed in the current work? How are the results and findings from the two studies related, if at all?

Reviewer \#2:

In this paper, the authors rather convincingly show that the ATG7 gene, which is critical for the initiation of autophagy and whose transcription decreases with aging, does contain a bona fide G-quadruplex (G4) in its first intron and that stabilization of G4 using pyridostatin (PDS), a well-known benchmark G4 ligand, downregulates this ATG7 gene. All this suggest that stabilization of ATG7 G4 does interfere with the transcription of this gene, thereby inhibiting induction of autophagy. In good agreement, the authors found that mice treated with PDS develop memory deficits and accumulation of lipofuscin, suggesting premature aging and deficient autophagy. Moreover, brain samples from aged mice contain G4-DNA which are absent in brain samples from young mice. Finally, the authors showed that overexpressing the helicase Pif1, which is known to resolve G4, in neurons exposed to PDS improves the various phenotypes associated with PDS treatment, thereby suggesting that G4-DNA may represent an interesting and relevant intervention point for boosting autophagy and thereby interfering with neurodegeneration.

In general, I think this is a very interesting study based on well-designed and well-conducted experiments that deserves to be published in *eLife*. In particular, revealing that G4 may represent a new putative intervention point to interfere with autophagy-related neurodegeneration represents an important discovery. Also, the idea that G4-ligands may induce/accelerate neurodegeneration is highly important, especially with respect to their putative development to the clinics in other field like cancerology. However, I have a few comments that need to be addressed before this paper could be deemed for publication in *eLife*.

\- Figure 1: the search for PQFS in the gene and promoter sequences of autophagy genes. The analysis performed by the authors indicates that all the autophagy genes contain putative G4-DNA. It would be important to precise the percentage of total genes that contain, or not putative G4-DNA to assess how specific is this correlation.

\- Figure 2: 2 µM PDS has a much stronger negative effect than 2 µM BRACO19 on the level of the ATG7 transcript. However, the effect on ATG7 protein level is similar for both compounds suggesting that BRACO19 could also interfere with translation of ATG7 mRNA or on ATG7 protein stability. The authors should comment on this. As for BRACO19, although it is very important to use another GA-ligand than PDS to support the authors\' main conclusions, it is somehow surprising that BRACO19 is used only in this experiment and also that its putative stabilizing effect on ATG7 G4-DNA is not properly assessed (see below).

\- Figure 3: The CD signature of the ATG7 gene in the classical conditions is not fully convincing and could correspond to a mix of several structures (not only G4). The authors argue that the presence of dehydrating agents (PEG, CH~3~CN) reduces the polymorphism and indeed the CD looks better but this effect has been reported only for telomeric sequences and is not fully admitted. Therefore, the salt effect (Li^+^ to K^+^) should preferably been tested using the HF2 antibodies. In line with what I discussed just above, BRACO19 should also be tested in the UV-melting experiments performed in panel c to determine if it also stabilizes, or not, the most probable ATG7 G4 and also in the experiments performed with N-TASQ on neurons in panels I & J. The TDS spectrum without dehydrating agents should also be shown. TDS and CD spectra should be shown on different panels and the CD in K^+^ conditions should not be termed \"cont\" (for control?) as it is misleading. Also, another classical control for CD which is missing is the use of scrambled G runs. Another important point is that the in vitro experiments presented in panels e to h should be repeated in presence, or not, of PDS or of BRACO19 to determine if these two G4 ligands may, or not, interfere with the binding of the HF2 antibody and/or of G4-binding proteins. This point looks important to me as the general assumption is that G4-ligands stabilize G4 structures but, in principle they could also destabilize them, and/or even prevent the binding of various factors such as antibodies or G4-binding proteins by direct competition. Finally, as for the experiments with N-TASQ, I have some problem to understand them because, as this fluorescent molecule is also a G4-ligand, one may imagine a competition between this compound and PDS for the binding on G4. And, indeed, in the original paper on N-TASQ (Laguerre et al., 2016), this problem is discussed and addressed (by using BRACO19 instead of PDS) and the authors concluded that at high concentration (100 µM) N-TASQ provides high resolution images but does not allow to visualize significant differences between BRACO19-treated and -untreated cells and that the only conditions that allowed to visualize an increase in N-TASQ stained nuclear foci was a low dose of N-TASQ (2.5 µM) and of BRACO19, and that a higher dose of BRACO19 leads to a BRACO19 dose-dependent decrease in N-TASQ staining, presumably because of a competition between these two G4-ligands for binding on G4. Hence it is hard for me to understand why and how PDS treatment should lead to an increase in N-TASQ staining (used at 50 µM here) as shown in panel i and j. Of note such a competition with PDS has been described for DAOTA-M2, another G4-specific fluorescent probe (Shivalingam et al., 2015). All this should be discussed and the effect of BRACO19 on N-TASQ staining should also be tested.

\- Figure 4: BRACO19 should also be tested in at least one of the experiments presented here as there are at the basis of the main conclusion of the paper, destabilization of DNA-G4 represents a relevant and interesting intervention point ATG7 to interfere with neurodegeneration associated with aging-related decline in induction of autophagy.

\- In the Discussion section, my suggestion is that the authors should discuss about the ability of G4-ligand to stabilize DNA-G4. Is it a general property of all the G4-ligands or is it specific to a subset of G4-ligands (that includes PDS and BRACO19)? Should a compound that efficiently bind G4 without any effect on their stability exist, then it would represent an ideal control to further validate their findings. Also the possibility that the PDS-related phenotypes may involve its effect on RNA-G4 should be mentioned and discussed.

To finish, and importantly, in my view the main message of this manuscript is that G4-DNA may represent an interesting and relevant intervention point for boosting autophagy and thereby interfering with neurodegeneration, rather than the discovery of a novel pathway that regulates autophagy in neurons, as stated by the authors already in the title. Indeed, if the authors want to state that their findings do reveal a novel pathway for regulating autophagy, than they need to find physiological situations where the stability of DNA-G4 present in autophagy genes (in particular in ATG7) may be tuned by various cellular pathway(s)/component(s) which, this way, regulate autophagy. As for now, they essentially showed that stabilizing G4 using PDS downregulates ATG7 and that PDS induces memory deficits and autophagy in mice and that, on the contrary, overexpressing the G4-DNA helicase Pif1 in neurons exposed to PDS suppresses PDS-associated phentotype. Not to mention that this G4 stabilization/PDS effect may also be at the level of G4-RNA. Therefore, I suggest that the authors down tune their message, especially in the Title but also in the discussion. I guess that revealing a new and relevant intervention point for modulating autophagy in neurons is per se sufficiently interesting in addition to be of biomedical relevance.

Reviewer \#3:

The authors used the G4 stabilizer pyridostatin (PDS) in cultured neurons and in mice to unravel a role for G4-DNA structures during Atg7-mediated autophagy. They used biophysical methods to demonstrate accumulation of G4-DNA in the Atg7 gene and immunostaining methods to illustrate an age-dependent global increase of G4-DNA. The authors further show that the majority of phenotypes induced by PDS were partially rescued by overexpression of fhe Pif1 helicase.

The manuscript is clearly written, and data are well presented. The implication of G4-DNA in autophagy and age-related neurological deficit is novel and will be of interest to a broad readership. It is not, however, clear if the effects reported here are direct consequences of G4-DNA in the Atg7 gene or indirect global perturbations of G4-DNA homeostasis. PDS is a blunt tool potentially impacting over 600,000 putative G4-DNA structures. Also, Pif1, as acknowledged by the authors, impacts telomere length, so how can the authors be sure that the reported partial improvements of neuronal phenotypes are solely due to resolving G4-DNA structures? Is the partial rescue specific to G4s in the Atfg7 gene? Performing a classical epistasis experiments is critical in this manuscript. For example, repeating key experiments in presence and absence of Atg7 will confirm that the reported phenotypes are due to direct modulation of G4-DNA in the Atg7 gene, hence supports the conclusion of a novel pathway as stated in the Title.

For the huntingtin experiments in Figure 4, I suggest using patient derived fibroblasts or iPS-derived striatal neurons instead of ectopic expression of the exon-1 fragment of the poly-Q huntingtin. Although, in silico predictions using the QGRS mapper rule out G4-DNA, it is important to experimentally rule it out in the native genomic environment.

The protein p62 is a known hallmark of perturbed autophagy. Is p62 aggregation also modulated by PDS in an Atg7 dependent manner? This is important since this hallmark protein aggregation is a common phenomenon in a number of age-associated neurological disorders including Huntington\'s and ALS/FTD. In the opinion of this reviewer, this is a better hallmark of perturbed autophagy given its clinical relevance.

Overall, the concept is novel and exciting but the data in its present form do not support the main conclusion.

\[Editors' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for submitting your article \"Small-molecule G-quadruplex stabilizers reveal a novel pathway of autophagy regulation in neurons\" for consideration by *eLife*. Your article has been reviewed by Michael Eisen as the Senior Editor, a Reviewing Editor, and two reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Sherif El-Khamisy (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript is a resubmission of a previous one in which authors show that the G-quadruplex (G4) ligand pyridostatin (PDS) was found to downregulate expression of the Atg7 gene in neurons. The first intron of the Atg7 gene contains predicted G4-forming sequences that seem to form G4 and interact with PDS. Mice treated with PDS develop memory deficits and accumulation of lipids and proteins previously observed to accumulate in aged brains. Brain samples from aged mice, but not young mice, contained G4 DNA, and overexpression of the G4-resolving helicase Pif1 in neurons improved the phenotypes associated with PDS treatment. Based on their findings, the authors conclude that G4 DNA is involved in regulating autophagy in neurons. The authors have satisfactorily responded to the concerns raised by the referees, but q few points need to be taken before the manuscript can be accepted.

Essential revisions:

\- The 3 quartet structure shown in Figure 3 has a low probability of formation due to the presence of 3 long loops (5-nt, 7-nt, 9-nt) which drastically reduce its stability (see various methods of the G4 score calculation in Bedrat et al., 2016; Puig-Lombardi et al., 2019). Hence it follows that the Atg7-32 sequence is most probably highly dynamic and may form several secondary structures that exist in equilibrium (various G4, hairpins etc.), which is good agreement with the very broad profile of the NMR spectra. Hence this analysis does not allow the authors to firmly conclude the existence of a stable G4. Therefore, the authors should down-tune, or at least modulate their G4 hypothesis.

\- The fact that Pif1 rescues PDS-induced phenotypes in cultured primary neurons (Figure 8). This observation is interesting but somehow a bit surprising and rather counter-intuitive as it is not fully consistent with numerous studies reported in the literature that show that the G4 unwinding activity of most of the G4 helicases is indeed prevented by G4 ligands. This has been shown in particular for Pif1 (see Mendoza et al., 2016; Mergny et al., 2015; Balasubramanian et al., 2015 plus references cited therein). Therefore, the assumption that Pif1 rescues PDS-induced phenotype by unwinding G4 in the Atg7 is unclear. The authors should discuss the results of their experiment with Pif1 in light of all the published data indicating that Pif1 G4 unwinding activity is inhibited by various G4 ligands that include PDS, or alternatively they could test their hypothesis by performing a functional in vitro assay (e.g.: unwinding assay with or without PDS).

10.7554/eLife.52283.sa2

Author response

\[Editors' note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors' response to the first round of review.\]

> Reviewer \#1:
>
> Summary:
>
> The G-quadruplex (G4) ligand pyridostatin (PDS) was found to downregulate expression of the Atg7 gene in neurons. The first intron of the Atg7 gene contains predicted G4-forming sequence that was indeed shown to form G4 and interact with PDS. Consistent with these findings, in vitro a G4 antibody and G4-binding protein bind to the Atg7 intron G4-sequence. In vivo, mice treated with PDS were found to develop memory deficits and accumulation of lipofuscin, a mixture of oxidized lipids and proteins previously observed to accumulate in aged brains. Brain samples from aged mice, but not young mice, contained G4 DNA, as evidenced by staining with G4-selective reagent. Overexpression of the G4-resolving helicase Pif1 in neurons improved phenotypes associated with PDS treatment, i.e., neuronal death. Based on their findings, the authors conclude that G4 DNA is involved in regulating autophagy in neurons.
>
> Critical Comments:
>
> \- The narrative of the Results section is noticeably deficient in making quantitative statements relating to the experimental data. This issue should be addressed throughout the Results section.

We thank the reviewer for this comment. We revised the manuscript to describe the results in greater detail, including quantitative statements for all of the results in the revised Results section.

> \- A useful control in the Pif1 rescue experiments would have been to test if a site-directed ATPase/helicase-dead mutant version of Pif1 failed to affect PDS-induced phenotypes in cultured primary neurons.

We thought this was an excellent suggestion, and we collected new data, which were added to the revised manuscript, to address this issue (Figure 8F). We cloned a site-directed ATPase/helicase-dead mutant version of Pif1 (E307Q) (George et al., 2009) and expressed it in primary neurons. Indeed, the mutant Pif1 failed to affect PDS-associated neuronal phenotypes---strong evidence that wild-type Pif1 activates coping mechanisms in PDS-treated degenerating neurons, leading to improved neuronal phenotypes, such as enhanced autophagy.

> \- Please define/explain Dendra2-LC3 half-life and how it is a reliable indicator of autophagy. It is mentioned in Figure 4 that LC3 is an autophagy marker. This should be better described in Results section and reference(s) provided.

The referee correctly points out that we only briefly described how protein (or organelle) half-life is measured with photoswitchable proteins and optical pulse-chase labeling (OPL). A number of studies used Dendra2 or other photoswitchable proteins, such as EOS2, and the OPL method to study protein or organelle dynamics in live cells. For example, mouse cell lines that express a mitochondrially localized Dendra2 (mito-Dendra2) were created to study mitochondrial dynamics and mitophagy (Pham, McCaffery and Chan, 2012). Another group created Dendra2-based PhOTO zebrafish for studying development and regeneration (Dempsey, Fraser and Pantazis, 2012). Dendra2-based OPL has been applied to study autophagy with Dendra2LC3 (Barmada et al., 2014; Moruno Manchon et al., 2015; Moruno Manchon et al., 2016); Tsvetkov et al., 2013) (LC3 is a marker of autophagy (Klionsky et al., 2016; Mizushima, Yoshimori and Levine, 2010), protein degradation (Barmada et al., 2014; Fernando, Rodriguez and Balasubramanian, 2008; Kwok and Merrick, 2017; Tsvetkov et al., 2013; Skibinski et al., 2017), and the dynamics of synaptic proteins (Wang et al., 2009). The journal Autophagy published a review paper, which recommended using Dendra2-LC3 to study autophagic flux in neurons (Klionsky et al., 2016). To measure autophagic flux in live neurons, we used the OPL method and longitudinal imaging (Barmada et al., 2014; Tsvetkov et al., 2013). Brief irradiation with short wavelength visible light irreversibly changes the conformation of "green" Dendra2 ("photoswitch") and its fluorescence to red. We can then track how the red signal (e.g., "red" Dendra2-LC3) is "cleared" over time and measure the half-life of Dendra2-LC3. This information and references have been added to the manuscript, thereby directly addressing the reviewer's concern.

> \- Aside from short-term memory as assayed by novel object recognition test, are there any other effects on mice treated with PDS in terms of development of memory deficits or neurological function/capacity? Were there any sex-specific effects?

We thank the reviewer for these questions. It took nearly 6 months to execute the requested experiments and revise the manuscript, primarily because the mice needed to reach a certain age to perform the requested task assays (we age our animals in house to control for diet/housing/microbiome effects). We apologize for this delay.

Regarding sex differences, we only used male mice in the original submission. This is a very important point and thus we prepared new cohorts of male and female mice that were injected with PDS. Previously, a G4-binding small molecule (MM41) was used as an anti-cancer therapy (Kulkarni, Chen and Maday, 2018); we therefore used a comparable dosage and schedule of PDS. We also used old male and female mice (25 months) with a leaky blood brain barrier (BBB) (Haeusle, Donnelly and Rothstein, 2016). All test were performed by an investigator blinded to treatment group. We examined *these* mice in (1) the novel object recognition test (NORT), (2) a fear conditioning test. We worked in collaboration with Dr. McCullough, who routinely uses animal models of stroke and has extensive expertise with behavior studies (<https://med.uth.edu/neurology/faculty/louise-d-mccullough-md-phd/>). First, we found that male and female mice injected with PDS performed significantly worse in the NORT (Figure 6A; \*p-value(male-cont vs PDS)=0.0265, \*pvalue(female-cont vs PDS)=0.0382, p-value(male vs female)=0.1029 (two-way ANOVA)). Second, mice were tested in the fear conditioning assay. The latter proved *extremely stressful* for old mice: they would frequently not move, making it difficult to analyze the data. Nevertheless, male mice performed worse in the fear conditioning assay. There was also a trend showing worse performance in the female cohort, although the data did not achieve statistical significance (see [Author response image 1](#respfig1){ref-type="fig"}). Due to the lack of mobility in the aged mice (which could be mistaken for "freezing"), we did not include these data into the manuscript.

![Two-way ANOVA, p value for control/PDS main effect is significant, p=0.0203, and the effects on male vs female is also significant, p=0.0326.](elife-52283-resp-fig1){#respfig1}

Sidak's multiple comparisons test shows that there is a significant difference between control and PDS within the male group after adjustment for multiple testing (p=0.0372), but not within the female group.

> \- The authors briefly mention in the Introduction the recently published paper by Beauvarlet et al., (April 2019) suggesting that G4 DNA in autophagic genes regulates autophagy in cancer cells. As cite in that work, there were several other previously published papers suggesting a connection of autophagy to G4 nucleic acid metabolism as probed by G4 ligands: Orlotti et al., (2012); Zhou et al., (2009); Zhou et al., (2009). While all these papers delved more into the relationships of G4 and autophagy in cancer, it would be useful to discuss these works in a single paragraph in the Discussion and place the current work in light of those findings.

We thank the reviewer for this comment. That is an excellent suggestion, as we indeed only briefly mentioned that a prior study investigated whether there is a relationship between G4-DNA, autophagy, and cancer. Critically, we did not emphasize that G4 ligands *stimulate* autophagy in cancer cells. In our study, we show the opposite: G4-DNA ligands downregulate autophagy in post-mitotic neurons, which comes as no surprise since the autophagic pathways in neurons differ from those in other cell types (Kulkarni, Chen and Maday, 2018).Therefore, we have taken this opportunity to review our discussion of the literature and to revise the manuscript to more effectively elaborate on the involvement of G4-DNA in autophagy and, importantly, on potential differences between neurons and cancer cells.

> \- In the Introduction, references should be provided for the statement that G4 has been implicated in neurodegenerative disorders frontotemporal dementia and ALS.

We added a reference to illustrate that the G4 structures play a role in frontotemporal dementia and ALS (Haeusler, Donnelly and Rothstein, 2016).

> \- In previous work by the authors, they reported that PDS promotes DNA damage and downregulates transcription of BRCA1 in neurons (Aging (2017)). The showed that overexpressed BRCA1 mitigates PDS-induced DNA damage. Similarly, in the current work does overexpression of ATG7 enzyme modulate the PDS-related phenotypes observed?

The experiments to address this question were technically challenging because our bioinformatics analyses revealed the presence of putative G4-DNA motifs in virtually all autophagy genes. However, importantly, many autophagy genes contain just a few putative G4-DNA motifs, whereas the *Rattus norvegicus Atg7* gene contains 27. As a result, transcription of *Atg7*, which diminishes with aging (Lipinski et al., 2010; Lu et al., 2004, can potentially be more sensitive to the G4-DNA ligands than transcription of other genes (autophagic and non-autophagic genes). These questions were not addressed in the current study and are currently being pursued in our lab. Nevertheless, for the resubmission, we cloned the cDNA of *Atg7*, which lacks a number of putative G4-DNA motifs located in the introns, including the 2700 G4-DNA under investigation. We applied single-cell longitudinal analysis to gain spatiotemporal resolution and to simultaneously visually monitor the accumulation of p62, an autophagy substrate and autophagic marker, and neuronal toxicity in neurons expressing ATG7-mApple treated with a vehicle or PDS. Indeed, we observed a rescue effect of overexpressed ATG7-mApple on the degradation of p62-GFP in the presence of PDS. We added the data to the revised manuscript (Figure 5---figure supplement 3).

> Is DNA damage accumulation in neurons also observed in the current work? How are the results and findings from the two studies related, if at all?

We thank the referee for this comment. We think this is a very important one. In our manuscript, we did not aim to conclude that the only way G4-DNA causes neurodegeneration is by downregulating autophagy. In our previous work, we showed that stabilizing G4-DNA leads to lower levels of *Brca1* andBRCA1 and, as a result, to accumulation of DNA damage (Moruno-Manchon et al., 2017). In the current manuscript, we showed that stabilizing G4-DNA strongly downregulates *Atg7*, ATG7, leading to reduced autophagy and neurotoxicity. At the same time, we cannot exclude the possibility that more factors may contribute to neurodegeneration. With that in mind, we agree with the reviewer and have discussed this issue in the manuscript.

Autophagic genes can be epigenetically silenced (Artal-Martinez de Narvajaset al., 2013; Baek and Kim, 2017; Lapierre et al., 2015). However, epigenetic silencing is a common mechanism in aged cells and affects the genes well beyond the autophagy pathway genes. In many models, the DNA damage repair genes and other gene types are epigenetically silenced in cancer and during aging (Lahtz and Pfeifer, 2011; Langie et al., 2017; Liu, Yip and Zhou, 2012). Our work suggests that an age-associated change in DNA conformation could be a *novel epigenetic-like mechanism* of gene expression in aging neurons; therefore, the results from our two studies are related. Please see the fourth paragraph in the Discussion section that describes this issue.

> Reviewer \#2:
>
> In this paper, the authors rather convincingly show that the ATG7 gene, which is critical for the initiation of autophagy and whose transcription decreases with aging, does contain a bona fide G-quadruplex (G4) in its first intron and that stabilization of G4 using pyridostatin (PDS), a well-known benchmark G4 ligand, downregulates this ATG7 gene. All this suggest that stabilization of ATG7 G4 does interfere with the transcription of this gene, thereby inhibiting induction of autophagy. In good agreement, the authors found that mice treated with PDS develop memory deficits and accumulation of lipofuscin, suggesting premature aging and deficient autophagy. Moreover, brain samples from aged mice contain G4-DNA which are absent in brain samples from young mice. Finally, the authors showed that overexpressing the helicase Pif1, which is known to resolve G4, in neurons exposed to PDS improves the various phenotypes associated with PDS treatment, thereby suggesting that G4-DNA may represent an interesting and relevant intervention point for boosting autophagy and thereby interfering with neurodegeneration.
>
> In general I think this is a very interesting study based on well-designed and well-conducted experiments that deserves to be published in eLife. In particular, revealing that G4 may represent a new putative intervention point to interfere with autophagy-related neurodegeneration represents an important discovery. Also, the idea that G4-ligands may induce/accelerate neurodegeneration is highly important, especially with respect to their putative development to the clinics in other field like cancerology. However, I have a few comments that need to be addressed before this paper could be deemed for publication in eLife.

We thank the reviewer for these comments.

> \- Figure 1: the search for PQFS in the gene and promoter sequences of autophagy genes. The analysis performed by the authors indicates that all the autophagy genes contain putative G4-DNA. It would be important to precise the percentage of total genes that contain, or not putative G4-DNA to assess how specific is this correlation.

We fear that we might not understand the referee's point. Here, we analyzed genes commonly described as "autophagy-related genes" in the autophagy literature. That means that other genes, even those that can potentially regulate autophagy directly or indirectly, were not taken into account in our analyses. We would like to point out that all of those genes were already analyzed for putative G4-DNA motifs by other labs Chambers, 2015).

> \- Figure 2: 2 µM PDS has a much stronger negative effect than 2 µM BRACO19 on the level of the ATG7 transcript. However, the effect on ATG7 protein level is similar for both compounds suggesting that BRACO19 could also interfere with translation of ATG7 mRNA or on ATG7 protein stability. The authors should comment on this.

We thank the reviewer for this comment. The interaction mechanisms between the G4 structures and PDS or BRACO19 differ in that BRACO19 is considered a "pan-quadruplex" ligand as it binds to quadruplexes whatever their secondary structures, and PDS is more selective for parallel-type quadruplexes (Ruggiero and Richter, 2018). Therefore, the fact that BRACO-19 and PDS affect levels of the *Atg7* transcript differently but levels of the ATG7 protein similarly could originate from selectivity of drugs for G4 structures. This point has been added to the discussion (please see the fifth paragraph in the Discussion section).

> As for BRACO19, although it is very important to use another GA-ligand than PDS to support the authors\' main conclusions, it is somehow surprising that BRACO19 is used only in this experiment and also that its putative stabilizing effect on ATG7 G4-DNA is not properly assessed (see below).

The reviewer is correct, of course: we should have used the BRACO19 ligand in other experiments as well (please see Figure 2, Figure 3 and Figure 4---figure supplement 1, Figure 5---figure supplement 1). BRACO19 downregulated ATG7 and Atg7, "slowed" melting Atg7-32, promoted the formation of N-TASQ puncta, inhibited autophagy and mitophagy.

> \- Figure 3: The CD signature of the ATG7 gene in the classical conditions is not fully convincing and could correspond to a mix of several structures (not only G4). The authors argue that the presence of dehydrating agents (PEG, CH~3~CN) reduces the polymorphism and indeed the CD looks better but this effect has been reported only for telomeric sequences and is not fully admitted. Therefore, the salt effect (Li+ to K^+^) should preferably been tested using the HF2 antibodies.

We agree that the use of dehydrating conditions to improve the CD signature of a quadruplex structure has not been examined thoroughly despite an initial impetus provided by Chaires et al.,2013). However, we also reported this effect for non-telomeric quadruplexes, extending this observation to quadruplex-forming sequences in the promoter of human genes (e.g., MYC, cf. Monchaud et al., 2014). To further address the reviewer's concerns about the ability of the ATG7 sequence to fold into a quadruplex structure, we performed a new series of experiments and added the data to the revised manuscript (Figure 3). Briefly, we performed an NMR experiment with ATG7-32 sequence ((d\[GGGGCTGGGGTCCCTTGGGGGAACTGTATTGGG\]) and compared the results with ATG7-32mut (d\[G[C]{.ul}G[C]{.ul}CTG[C]{.ul}G[C]{.ul}TCCCTTG[C]{.ul}G[C]{.ul}AACTGTATTG[C]{.ul}G\]), a sequence that cannot fold into quadruplex. For the HF2 binding experiment, we determined the effects of K^+^ (known G4 stabilizing cation) and Li^+^ (known G4-destabilizing cation) and saw clear, expected results (Figure 4A,B).

![](elife-52283-resp-fig2){#respfig2}

The results seen in [Author response image 2](#respfig2){ref-type="fig"} clearly indicated that ATG7-32 folds into a complex structure comprising both a quadruplex core (^1^H-NMR signals between 10 and 12 ppm) and duplex stems (^1^H-NMR signals between 12.5 and 14 ppm), which explains the complicated CD signature, whereas ATG7-32mut displays only duplex stem contribution. Of note, the polymorphism of the ATG7-32 quadruplex is also obvious, given the low resolution of the signal in the region of the NMR signals typical of the quadruplex core. Again, these results further substantiate the complicated CD signature observed in 'native' (that is, without dehydrating agent) conditions.

> In line with what I discussed just above, BRACO19 should also be tested in the UV-melting experiments performed in panel c to determine if it also stabilizes, or not, the most probable ATG7 G4 and also in the experiments performed with N-TASQ on neurons in panels I and J.

We thank the reviewer for this comment. We added the data to the revised manuscript (Figure 3, Figure 4---figure supplement 1).

> The TDS spectrum without dehydrating agents should also be shown. TDS and CD spectra should be shown on different panels and the CD in K^+^ conditions should not be termed \"cont\" (for control?) as it is misleading. Also, another classical control for CD which is missing is the use of scrambled G runs.

We agree and apologize for this oversight. We performed the requested experiments and presented the data splitting the CD and TDS results (left and right panel, respectively; Figure 3C,D).

The results seen in Figure 3 indicate clearly the topological differences between ATG7-32 and its mutated counterpart, the latter being characterized by both a CD signature (cf. Vorlickova et al., 2009) and a TDS signature (cf. Mergny et al., 2005) typical of a duplex structure with high GC content.

> Another important point is that the in vitro experiments presented in panels e to h should be repeated in presence, or not, of PDS or of BRACO19 to determine if these two G4 ligands may, or not, interfere with the binding of the HF2 antibody and/or of G4-binding proteins. This point looks important to me as the general assumption is that G4-ligands stabilize G4 structures but, in principle they could also destabilize them, and/or even prevent the binding of various factors such as antibodies or G4-binding proteins by direct competition.

We thank the referee for this comment. We fear, however, that it is not easy to address their concern. First, the precise mode of binding of the antibody HF2 to G4s is not known. HF2 might discriminate between various quadruplexes from the KIT gene (cf. Balasubramanian et al., 2008), but the lack of solid structural data precludes any attempt to rationalize the way it binds to quadruplex. Second, it has also been demonstrated with another quadruplex-selective antibody, BG4, that the concomitant binding of both an antibody (BG4) and a ligand (cPDS) is possible (cf. Balasubramanian et al., 2015). Third, examples of quadruplex-destabilizing agents are still very sparse in the literature, and reported examples (e.g., TMPyP4, cf. Pearson et al., 2014) have been collected under debatable experimental conditions (e.g., very high ligand/DNA ratio), far from any biological relevance. Therefore, performing experiments in presence of both antibodies and ligands is possible, but the many possible outcomes (e.g., competition, cooperation) make the exploitation of the results far too complex to be attempted. Nevertheless, we again thank the reviewer for this comment and will address this in future experiments.

> Finally, as for the experiments with N-TASQ, I have some problem to understand them because, as this fluorescent molecule is also a G4-ligand, one may imagine a competition between this compound and PDS for the binding on G4. And, indeed, in the original paper on N-TASQ (Laguerre et al., 2016), this problem is discussed and addressed (by using BRACO19 instead of PDS) and the authors concluded that at high concentration (100 µM) N-TASQ provides high resolution images but does not allow to visualize significant differences between BRACO19-treated and -untreated cells and that the only conditions that allowed to visualize an increase in N-TASQ stained nuclear foci was a low dose of N-TASQ (2.5 µM) and of BRACO19, and that a higher dose of BRACO19 leads to a BRACO19 dose-dependent decrease in N-TASQ staining, presumably because of a competition between these two G4-ligands for binding on G4. Hence it is hard for me to understand why and how PDS treatment should lead to an increase in N-TASQ staining (used at 50 µM here) as shown in panel i and j. Of note such a competition with PDS has been described for DAOTA-M2, another G4-specific fluorescent probe (Shivalingam et al., 2015). All this should be discussed and the effect of BRACO19 on N-TASQ staining should also be tested.

We thank the reviewer for this comment and apologize if our explanation was not clear in the initial manuscript. Briefly, the most important parameters to control are the live-cell incubation of the quadruplex ligand (e.g., PDS, BRACO19 -- with ad hoc concentrations) and the post-fixation cell labelling with N-TASQ (at a concentration that must be fine-tuned). This protocol, which allows for assessing the extent (and modification) of the quadruplex landscape upon ligand treatment, was developed with MCF7 cells (cf. Monchaud et al., 2016) and subsequently validated in HeLa cells (in presence of either BRACO19 or TMPyP4, cf. Monchaud et al., 2017). Importantly, this protocol was used with cancer cells but never with neurons, and the collected results presented here lend further credence to its reliability and broad applicability.

> \- Figure 4: BRACO19 should also be tested in at least one of the experiments presented here as there are at the basis of the main conclusion of the paper, destabilization of DNA-G4 represents a relevant and interesting intervention point ATG7 to interfere with neurodegeneration associated with aging-related decline in induction of autophagy.

As discussed above, there are no reliable examples of small molecules reported as quadruplex-destabilizing agents, apart from somewhat debatable candidates. Specifically, the role of BRACO19 in destabilizing G4-DNA remains questionable in light of the many recent reports (e.g., over 50 articles published on BRACO19).

> \- In the Discussion section, my suggestion is that the authors should discuss about the ability of G4-ligand to stabilize DNA-G4. Is it a general property of all the G4-ligands or is it specific to a subset of G4-ligands (that includes PDS and BRACO19)? Should a compound that efficiently bind G4 without any effect on their stability exist, then it would represent an ideal control to further validate their findings. Also, the possibility that the PDS-related phenotypes may involve its effect on RNA-G4 should be mentioned and discussed.

We thank the reviewer for their comments. We substantially expanded the Discussion section. Please see the fifth paragraph of the Discussion section.

> To finish, and importantly, in my view the main message of this manuscript is that G4-DNA may represent an interesting and relevant intervention point for boosting autophagy and thereby interfering with neurodegeneration, rather than the discovery of a novel pathway that regulates autophagy in neurons, as stated by the authors already in the title. Indeed, if the authors want to state that their findings do reveal a novel pathway for regulating autophagy, than they need to find physiological situations where the stability of DNA-G4 present in autophagy genes (in particular in ATG7) may be tuned by various cellular pathway(s)/component(s) which, this way, regulate autophagy. As for now, they essentially showed that stabilizing G4 using PDS downregulates ATG7 and that PDS induces memory deficits and autophagy in mice and that, on the contrary, overexpressing the G4-DNA helicase Pif1 in neurons exposed to PDS suppresses PDS-associated phentotype. Not to mention that this G4 stabilization/PDS effect may also be at the level of G4-RNA. Therefore, I suggest that the authors down tune their message, especially in the Title but also in the discussion. I guess that revealing a new and relevant intervention point for modulating autophagy in neurons is per se sufficiently interesting in addition to be of biomedical relevance.

We thank the referee for these comments. In our original submission, we showed that (1) stabilizing G4s downregulates *Atg7*, ATG7, and autophagy; (2) old brains contain more G4s but young brains hardly any; (3) *Atg7* is downregulated in old brains; (4) Pif1 rescues phenotypes associated with PDS treatment (e.g., autophagic phenotypes); and (5) the expression of Pif1 itself slightly upregulates autophagy in neurons. We, therefore, speculated in the Discussion section that in addition to histone acetyltransferases facilitating chromatin decondensation and promoting the expression of autophagy-related genes (Baek and Kim, 2017; Lapierre et al., 2015), Pif1 may help to sterically allow the transcriptional machinery to transcribe DNA. To respond to the reviewer's conceptual concerns, we performed additional experiments with an ATPase/helicase-dead mutant version of Pif1 (also requested by reviewer 1) and added the results to the revised manuscript (Figure 8F). Mutated Pif1 was not able to rescue autophagic phenotypes in neurons. Therefore, while we are delighted that the reviewer is accepting of the main conclusions of our study, we respectfully disagree with the reviewer's assessment of "the main message." We believe that our study revealed a new epigenetic-like mechanism of autophagy regulation in neurons. Our conclusions reflect the prevailing views in the autophagy field (Lapierre et al., 2015), as the field is highly interested in understanding *why autophagy is diminished in neurons with aging*, leading to age-associated neurodegenerative disorders. Nevertheless, we have taken this opportunity to review our description/discussion of these findings and to revise them to more effectively explain the main conclusions without overstating the significance.

> Reviewer \#3:
>
> The authors used the G4 stabilizer pyridostatin (PDS) in cultured neurons and in mice to unravel a role for G4-DNA structures during Atg7-mediated autophagy. They used biophysical methods to demonstrate accumulation of G4-DNA in the Atg7 gene and immunostaining methods to illustrate an age-dependent global increase of G4-DNA. The authors further show that the majority of phenotypes induced by PDS were partially rescued by overexpression of fhe Pif1 helicase.
>
> The manuscript is clearly written, and data are well presented. The implication of G4-DNA in autophagy and age-related neurological deficit is novel and will be of interest to a broad readership.

We thank the referee for these comments.

> It is not, however, clear if the effects reported here are direct consequences of G4-DNA in the Atg7 gene or indirect global perturbations of G4-DNA homeostasis. PDS is a blunt tool potentially impacting over 600,000 putative G4-DNA structures. Also, Pif1, as acknowledged by the authors, impacts telomere length, so how can the authors be sure that the reported partial improvements of neuronal phenotypes are solely due to resolving G4-DNA structures? Is the partial rescue specific to G4s in the Atfg7 gene?

Reviewer 1 raised a similar question. Initially, we viewed G4s as pathogenic DNA and RNA structures that occur only in some neurodegenerative diseases (e.g., frontotemporal dementia and ALS (Haeusler, Donnelly and Rothstein, 2016). However, analyses of the aged brain samples with *no* neurodegenerative pathologies led to a surprising and serendipitous finding---that the G4 structures are present in the aged brains and could be a marker of [senescence]{.ul} in aging cells (e.g., as DNA methylation or aneuploidy or transposable element dysregulation in neurons (Mosch et al., 2007; Fischer et al., 2012; Sun et al., 2018)). By the end of the study, we understood that the Pif1 helicase can partially rescue "aging" autophagic phenotypes. Therefore, at a larger scale, we view our data on an age-associated change in DNA conformation as a novel epigenetic-like mechanism of gene expression in aging neurons. Recently, transposable elements were found to be epigenetic regulators of the genome, opening a new avenue of exciting research in neurodegeneration (Sun et al., 2018). We believe that G4-DNA is an additional layer for such epigenetic-like regulation. As an autophagy lab interested in neuronal autophagy (Moruno Manchon et al., 2016; Tsvetkov et al.,2013; Moruno Manchon et al., 2015; Moruno Manchon et al., 2016), we started investigating the roles of G4-DNA in neuronal aging with assessing their role in autophagy. Please see the fourth paragraph in Discussion section, which discusses this important issue.

Neurons are post-mitotic and how telomere length could be affected by Pif1 is not exactly clear. Indeed, cell-cycle activity is a driving force for telomere shortening. In some neurodegenerative diseases and in advanced aging, post-mitotic neurons re-enter the cell cycle, leading to various DNA abnormalities (Mosch et al., 2007; Fischer et al., 2012). Neurons with a shorter telomere length can be generated from aged fibroblasts (Huh et al., 2016. We believe it is unlikely that Pif1 is neuroprotective due to a telomere effect. As Pif1 is a G4-DNA helicase and its function to unwind G4-DNA, its beneficial effects are likely due to a helicase activity. Indeed, in the revised manuscript, we show that a helicase dead mutant lost its effect (Figure 8F). Nevertheless, we cannot fully exclude the possibility that Pif1 may have additional unknown functions besides being a G4-DNA helicase.

Above we explained our motivation for studying the *Atg7* gene (please see our response to reviewer 1's comments). Briefly, among ATG-related genes, *Atg7* contains one of the highest amount of putative G4 motifs, and it works at the very beginning of the initiation of autophagy. As we believe that G4-DNA functions by means of an epigenetic like mechanism, Pif1's rescue effect is not specific to *Atg7*.

> Performing a classical epistasis experiments is critical in this manuscript. For example, repeating key experiments in presence and absence of Atg7 will confirm that the reported phenotypes are due to direct modulation of G4-DNA in the Atg7 gene, hence supports the conclusion of a novel pathway as stated in the Title.

We thought this was an excellent suggestion. We collected new data, which are now added to the revised manuscript, to address the reviewer's suggestion (Figure 5---figure supplement 3).

> For the huntingtin experiments in Figure 4, I suggest using patient derived fibroblasts or iPS-derived striatal neurons instead of ectopic expression of the exon-1 fragment of the poly-Q huntingtin. Although, in silico predictions using the QGRS mapper rule out G4-DNA, it is important to experimentally rule it out in the native genomic environment.

As we study autophagy in the lab, we frequently use mutant huntingtin as a marker of autophagic clearance effectiveness. Huntingtin is a big protein (\>3,300 amino acids), and its gene contains numerous putative G4-DNA motifs. Its half-life is quite long, however, and so, we can assess huntingtin degradation before PDS-associated effects on the huntingtin gene's transcription. We cultured primary neurons from BACHD mice to determine if PDS affects the levels of mutant huntingtin. BACHD mice from the Yang lab (UCLA) express a human mHtt (97Qs) genomic locus and flanking sequences. The BACHD model recapitulates many of the molecular/cellular/behavior features seen in Huntington disease patients (Gray et al., 2008). PDS promoted accumulation of mutant huntingtin indicating that the degradative pathways in neurons are affected by PDS (Figure 5---figure supplement 2).

> The protein p62 is a known hallmark of perturbed autophagy. Is p62 aggregation also modulated by PDS in an Atg7 dependent manner? This is important since this hallmark protein aggregation is a common phenomenon in a number of age-associated neurological disorders including Huntington\'s and ALS/FTD. In the opinion of this reviewer, this is a better hallmark of perturbed autophagy given its clinical relevance.
>
> Overall, the concept is novel and exciting but the data in its present form do not support the main conclusion.

We thought this was a great suggestion. We collected new data, which are now added to the revised manuscript (Figure 5---figure supplement 3). We are pleased that this reviewer accepts the novelty of our study and hope that the new data support the conclusions of our manuscript.

Additional References:

Dempsey, W.P., Fraser, S.E. & Pantazis, P. PhOTO zebrafish: a transgenic resource for in vivo lineage tracing during development and regeneration. PLoS One 7, e32888 (2012).

\[Editors' note: what follows is the authors' response to the second round of review.\]

> The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.
>
> Summary:
>
> This manuscript is a resubmission of a previous one in which authors show that the G-quadruplex (G4) ligand pyridostatin (PDS) was found to downregulate expression of the Atg7 gene in neurons. The first intron of the Atg7 gene contains predicted G4-forming sequences that seem to form G4 and interact with PDS. Mice treated with PDS develop memory deficits and accumulation of lipids and proteins previously observed to accumulate in aged brains. Brain samples from aged mice, but not young mice, contained G4 DNA, and overexpression of the G4-resolving helicase Pif1 in neurons improved the phenotypes associated with PDS treatment. Based on their findings, the authors conclude that G4 DNA is involved in regulating autophagy in neurons. The authors have satisfactorily responded to the concerns raised by the referees, but q few points need to be taken before the manuscript can be accepted.
>
> Essential revisions:
>
> \- The 3 quartet structure shown in Figure 3 has a low probability of formation due to the presence of 3 long loops (5-nt, 7-nt, 9-nt) which drastically reduce its stability (see various methods of the G4 score calculation in Bedrat et al., 2016; Puig-Lombardi et al., 2019). Hence it follows that the Atg7-32 sequence is most probably highly dynamic and may form several secondary structures that exist in equilibrium (various G4, hairpins etc.), which is good agreement with the very broad profile of the NMR spectra. Hence this analysis does not allow the authors to firmly conclude the existence of a stable G4. Therefore, the authors should down-tune, or at least modulate their G4 hypothesis.

The referees correctly point out that we only briefly described how Atg7-32 may fold into several secondary structures that likely exist in an equilibrium. Therefore, we reviewed our explanation of the results and revised the manuscript to more effectively elaborate on how Atg7-32 may form various structures. In particular, we re-wrote the paragraph that explains the observed data and it now reads as the following.

"We further investigated the higher-order structure of both Atg7-32 and mutAtg7-32 by nuclear magnetic resonance (NMR). Both displayed ^1^H-NMR signals in the 12--14 ppm region, which corresponds to duplex stems (providing a rationale for the complicated CD/TDS signature of the former), but only Atg7-32 had ^1^H-NMR signals in the 10--12 ppm region, characteristic of a G4-DNA structure (poorly defined here, indicating a mixture of G4 topologies) (Figure 3E). These signals indicate that Atg7-32 may fold into a variety of G4-DNA topologies, including both 3- and 4-G-quartet G4s with both short (2-nt) and long (9-nt) hairpin-forming loops (Figure 3B), which were also detected earlier in non-neuronal cells^3,40^ or computationally predicted^41,42^. An equilibrium among all these various topologies is illustrated by the complex signatures generated with CD, TDS and NMR."

In addition, we removed the word "stable" from the following sentence in the Discussion: "We showed that a PQFS identified in the Atg7 gene can fold into a G4 structure, as demonstrated by spectroscopy (CD, TDS and NMR) and its interaction with PDS and BRACO-19, the HF2 antibody, and the G4-binding protein PC4".

We also thank the referees for the references. In addition to citing Bedrat et al., 2016 and Puig-Lombardi et al., 2019, we now included a citation for Chambers et al., 2015, as Chambers et al., specifically emphasized the following: "To understand the potential functions of G4s, we quantified the prevalence of OQs in genomic regions associated with promoters, 3′ and 5′ untranslated regions (UTRs), exons, introns and splicing junctions (Supplementary file 4). Notably, a large proportion of these regions (up to 49% in PDS and 46% in K^+^) compose exclusively noncanonical G4s (i.e., long loops or bulges)". Please see the new Figure 3B that illustrates these possibilities.

> \- The fact that Pif1 rescues PDS-induced phenotypes in cultured primary neurons (Figure 8). This observation is interesting but somehow a bit surprising and rather counter-intuitive as it is not fully consistent with numerous studies reported in the literature that show that the G4 unwinding activity of most of the G4 helicases is indeed prevented by G4 ligands. This has been shown in particular for Pif1 (see Mendoza et al., 2016; Mergny et al., 2015; Balasubramanian et al., 2015 plus references cited therein). Therefore, the assumption that Pif1 rescues PDS-induced phenotype by unwinding G4 in the Atg7 is unclear. The authors should discuss the results of their experiment with Pif1 in light of all the published data indicating that Pif1 G4 unwinding activity is inhibited by various G4 ligands that include PDS, or alternatively they could test their hypothesis by performing a functional in vitro assay (e.g.: unwinding assay with or without PDS).

We thank the referees for this comment. That is an excellent suggestion, as we indeed did not discuss that several prior studies investigated how an unwinding activity of G4 helicases is affected by G4-ligands (e.g., PDS). We did not emphasize that several previous studies reported that, in general, G4-ligands impede helicase functions. In our study, we show the opposite: the PIF1 helicase rescues PDS-associated phenotypes in living neurons.

We would like to point out that others published exciting studies on the helicase/G4-ligand assays focused on in vitro systems only. Therefore, the relevance of their findings to our study is not that straightforward. For example, these in vitro studies used an excess of the G4-ligands that may have a strong effect on the outcome.

Critically, these studies used a G4-forming sequence without its complementary sequence in the in vitro assays. In these assays, adding the complementary sequence (so called the "trap" oligonucleotide) fully unfolds the G4-DNA/ligand complexes (Mendoza et al., 2016). In contrast, our study focused on how PIF1 rescues PDS-associated phenotypes in living neurons. Our in vivo context and low concentrations of PDS may explain why our data are different from those generated in vitro. Finally, in our neuronal system, primary neurons are transfected with PIF1, and PDS is later added---after PIF1 becomes overexpressed. We have taken this opportunity to review our discussion of the literature and to revise the manuscript to meticulously explain the main conclusions, as follows.

"Intriguingly, prior in vitro studies found that Pif1's G4-DNA unwinding activity is diminished by G4 ligands (e.g., PDS), which appears to contradict to our in vivo findings. Nevertheless, the relevance of these data to our study is not straightforward since a G4-DNA forming sequence was used without its complementary sequence in the in vitro studies. Adding the complementary DNA sequence unfolds the G4-DNA/ligand complexes^84^. In addition, the in vitro experiments assayed the activity of Pif1 using an excess of G4 ligands^84^, and therefore, the data are not easy to extrapolate to our neuronal in vivo model. Also, in our studies with living neurons, Pif1 was overexpressed before PDS was added to the media, and thus, the kinetics of Pif1-G4-DNA-PDS interactions may be overly complex for a direct comparison to the in vitro conditions."
